Edited for the British Pharmacological Society by

C.T. Dollery (Chairman) A. Richens (Secretary) Annmarie Hedges (Press Editor) T.B. Binns A.F. Lant A. Breckenridge G. Mawer W. Watson Buchanan D.G. McDevitt D.B. Caine A.N. Nicholson T. Chard F. O'Grady J. Crooks J.P. Payne D.A.P. Evans B.N.C. Prichard C.F. George M. Rawlins A. Goldberg J. Reid D. Grahame-Smith R.G. Shanks I.W.B. Grant F.O. Simpson R.L. Hodge J.R. Trounce M.H. Lader D.W. Vere O.L. Wade

Papers will be considered for publication on all aspects of drug action in man. Manuscripts (two copies) should be sent to Professor A. Richens, Department of Pharmacology and Materia Medica, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XN. The instructions to authors are printed in volume 1 (pages 3 to 6) ofthe journal. Details of the SI symbols for units can be found in the January 1974 issue (volume 50, pages 6 to 23) of the British Journal ofPharmacology. British Journal of Clinical Pharmacology is published monthly by Scientific & Medical Division, Macmillan Publishers Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: Basingstoke 29242. ISSN 0306-5251. Annual subscription: UK £75.00; USA & Canada, US$185; Rest of world, £89; Airmail £102 (or equivalent in any other currency). (Orders must be accompanied by remittance. Prices correct at time of publication.) Cheques should be made payable to Macmillan Journals Limited: Subscription Department, Brunel Road, Basingstoke, Hampshire RG21 2XS, England. Where appropriate, overseas subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Enquiries concerning advertising space or rates should be addressed to: Advertisement Department, Macmillan Journals Limited, 4 Little Essex Street, London WC2R 3LF. Telephone: 01-836 6633. Copyright ©) 1981 by the British Journal of Clinical Pharmacology. All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world. Second class postage paid at New York, N.Y. US Mailing Agent: Expediters of the printed Word, Inc., Suite 1217, 527 Madison Ave., New York, N.Y. 10022. INDEX TO VOLUME 11 AUTHOR INDEX

A ABEYASEKERA, G. see BRODIE, M.J., 422P ELLIS, A., HALL, J.M., MACIVER, M., ORME, ADDIS, G.J. see BARCLAY, JOYCE, 203 M.I'E. & ROWE, P.H. The in vitro metabolism of AELLIG, W.H. A new technique for recording compliance ethinyloestradiol, mestranol and levonorgestrel by of human hand veins, 237 human jejunal mucosa, 275 AHMAD, R.A. & ROGERS, H.J. Salivary elimination of BACK, D.J. see CRAWFORD, FRANCESCA E., 438P pyrimethamine, 101 BAIRD, G.M., LAWRENCE, J.R., STEELE, W.H. & AITIO, ANTERO see AITIO, MIRJA-LIISA, 279 WILLOUGHBY, M.L.N. Salivary levels of metho- AITIO, MIRJA-LIISA. Plasma concentrations and protein trexate (MTX) as an index of CSF levels in children: a binding of disopyramide and mono-N-dealkyl- pilot study, 112P disopyramide during chronic oral disopyramide therapy, BAKER, J.R., PECK, C.C., RAYBUCK, B.D., OWENS, 369 E.L. & SCHUSTER, B.G. Normal pharmacokinetics of AITIO, MIRJA-LIISA, MANSBURY, LEENA, TALA, doxapram in a patient with renal failure and EERO, HAATAJA, MATTI & AITIO, ANTERO. hypothyroidism, 305 The effect of enzyme induction on the metabolism of BAKKE, O.M. see ASLAKSEN, A., 269 disopyramide in man, 279 BAKRAN, I. jr see PLAVSIC, F., 533 ALBAN DAVIES, H., RHODES, J. & THOMAS, M. BALANT, L. see COCHET, B., 389 Inhibition of gastric acid secretion with mast cell stabil- BALNAVE, K., NEILL, J.D., RUSSELL, C.J., izer, FPL-52694, 53 HARRON, D.W.G., LEAHY, W.J., WILSON, R. & ALBERTI, K.G.M.M. see THOM, S., 423P SHANKS, R.G. Observations on the efficacy and phar- ALLAZ, A.-F. see COCHET, B., 389 macokinetics of betaxolol (SL 75212), a cardioselective ALLEN, MARCIA D. see GREENBLATT, D.J., 35 f-adrenoceptor blocking drug, 171 ALLEN, R. see ORR, M.W., 255 BARBAT, J., WARRINGTON, S.J., WEERASURIYA, ALLONEN, H. see KANTO, J., 629 K. & PATEL, LATA (introduced by TURNER, P.). ALVAN, G., BERGMAN, U. & GUSTAFSSON, L.L. Effect of hydralazine on systolic time intervals, 1 1 7P High unbound fraction of salicylate in plasma during BARBER, H.E., HAWKSWORTH, G.M., PETRIE, J.C., intoxication, 625 RIGBY, J.W., ROBB, O.J. & SCOTT, A.K. Phar- AMESS, J. see TREMBATH, P.W., 19 macokinetics of atenolol and propranolol in young and ANKIER, S.I., MARTIN, B.K., ROGERS, M.S., CAR- elderly subjects, 118P PENTER, P.K. & GRAHAM, C. Trazodone - a new BARBER, H.E., PETERSEN, J. & WHITING, P.H. The assay procedure and some pharmacokinetic parameters, effects of either frusemide or piretanide on the phar- 505 macokinetics of gentamicin, 113P AMICO, A. see MORETTI, A., 511 BARBER, H.E. see WEBSTER, J., 333 ASLAKSEN, A., BAKKE, O.M. & VIGANDER, T. Com- BARBIERI, R., CALDARA, R. & FERRARI, C. Clinical parative pharmacokinetics of theophylline and pharmacology of prazosin: further discussion, 314 aminophylline in man, 269 BARCHOWSKY, A. see ROUTLEDGE, P.A., 245 AUSTIN, K.L., STAPLETON, J.V. & MATHER, L.E. BARCLAY, JOYCE, WHITING, B., MEREDITH, P.A. Pethidine clearance during continuous intravenous infu- & ADDIS, G.J. Theophylline-salbutamol interaction: sions in postoperative patients, 25 bronchodilator response to salbutamol at maximally AWADZI, K., BELL, D.R., BRECKENRIDGE, A.M., effective plasma theophylline concentrations, 203 GILLIES, H.M., HADDOCK, D.R. & ORME, M.l'E. BARNABA, A. see FURLANUT, M., 393 The effect of indomethacin, prednisone and cyprohep- BARNETT, D.B., DAVIES, A.T. & DESAI, N. Differen- tadine in suppressing the adverse reactions following the tial effect of diazepam on short term memory in subjects use of diethylcarbamazine in patients with onchocer- with high or low level anxiety, 41 1P ciasis, 418P BARNETT, D.B., FREEMONT, A.J. & O'MALLEY, B.P. Comparison of plasma levels after conventional and long acting propranolol using a radioreceptor assay, 432P BARTLETT, J. see NEIL-DWYER, G., 549 B BARUZZI, A. see TEDESCHI, G., 618 BATEMAN, D.N. & RAWLINS, M.D. Prazosin BAARS, A.M. see van der KLEUN, E., 85S concentration-effect, metabolism and biological activity BACK, D.J., BATES, M., BRECKENRIDGE, A.M., of metabolites, 221 636 INDEX

BATES, M. see BACK, D.J., 275 BROWN, M.J. see JENNER, D.A., 435P BATESON, M.C., FIABANE, A.M., CLARKE, A. & BROWN, K., HODDER, R.W. & NEALE, M.G. Plasma BOUCHIER, I.A.D. Probucol and hypercholes- concentrations of sodium cromoglycate in volunteers terolaemia, 531 determined by a new method, 425P BAXI, A.J. see SHETH, U.K., 251 BRUNNER, D.B., DEPONDS, G., BIOLLAZ, J., KEL- BELAIEFF, J. see COCHET, B., 389 LER, I., BRUNNER, H.R. & SCHELLING, J.L. Effect BELL, D.R. see AWADZI, K., 418P of a new angiotensin converting enzyme inhibitor BELPAIRE, F.M., BOGAERT, M.G., ROSSENEU, M. & MK 421 and its lysine analogue on the components of TEIRLYNCK, 0. Binding of 3-adrenoceptor antagon- the renin system in healthy subjects, 461 ists to human serum albumin, al-acid glycoprotein and BRUNNER, H.R. see BRUNNER, D.B., 461 human serum, 125P BRUNT, P.W. see WEBSTER, J., 333 BENNETT, P.N., DIXON, A.St.J., NOTARIANNI, BUCKINGHAM, JULIA C. Neural mechanisms control- LIDIA J. & OLDHAM, HARRIET G. Paracetamol ling the secretion of corticotrophin releasing factor, 216 metabolism in overdosed patients, 1 1OP BULLOCK, D.W. see REEVES, D.S., 353 BERGMAN, U. see ALVAN, G., 625 BURGESS, C. see HAMER, J., 426P BHATT, ASHA M., PLEUVRY, BARBARA J. & MAD- BYRNE, C. see SALTISSI, S., 497 DISON, STEPHANIE E. Respiratory and metabolic BYWATER, M.J. see REEVES, D.S., 353 effects of oral nefopam in human volunteers, 209 BIANCHETTI, G. see TEDESCHI, G., 430P BIOLLAZ, J. see BRUNNER, D.B., 461 BITT'ENCOURT, P., WADE, P., LLOYD, D., SMITH, C A.T., TOSELAND, P.A. & RICHENS, A. Relation- ship between serum benzodiazepine concentration and CACCIA, C. see MORETTI, A., 511 peak velocity of saccadic eye movements, 437P CALDARA, R. see BARBIERI, R., 314 BLACK, A.K., FINCHAM, N., GREAVES, M.W. & CALVEY, T.N., CHAN, K., DEHGHAN, A. & WIL- HENSBY, C.N. Time course changes in levels of LIAMS, N.E. Kinetics of intravenous pyridostigmine in arachidonic acid and prostaglandins D2, E2, F2C,, and man, 406 6-oxo-PGF1, in human skin following ultraviolet B CALVEY, T.N., CHAN, K., MILNE, L.A., MURRAY, irradiation, 109P G.R. & WILLIAMS, N.E. Plasma levels and urinary BLACKETT, A.N. see SHARMA, J.N., 433P excretion of phenoperidine and its metabolites in volun- BLAIR, I.A. see BOOBIS, A.R., 419P teer subjects, 124P BLANCK, K.J. see JAHNCHEN, E., 361 CAMPBELL, B.C., ELLIOTT, H.L., HUGHES, M.A., BLOOMFIELD, S.S. & HANKS, G.W. The visual MCLEAN, K., MEREDITH, P.A. & REID, J.L. Effect analogue scale, 98 of food on the pharmacokinetics of tolmesoxide in BOELAERT, J. see HALLYNCK, TH., 523 hypertensive patients, 431P BOGAERT, M.G. see BELPAIRE, F.M., 125P CAMPBELL, B.C., REID, J.L. & SHEPHERD, A.N. The BONOLLO, L. see MARTINI, A., 605 effects of captopril on blood pressure, converting en- BONOLLO, L. see MARTINI, A., 611 zyme activity, plasma angiotensin I concentration, renin BONOLLO, L. see MORETTI, A., 511 activity and noradrenaline concentration in normoten- BOOBIS, A.R., BRODIE, M.J., KAHN, G.C., TO- sive sodium replete volunteers, 121 P VERUD, E.-L., BLAIR, I.A., MURRAY, S. & CANNINGS, R., NICHOLSON, A.N. & STONE, BAR- DAVIES, D.S. Comparison of in vivo and in vitro rates BARA M. Contingent negative variation: Studies with a of antipyrine oxidation in man, 419P benzodiazepine, 410P BOOBIS, A.R. see BRODIE, M.J., 422P CARPENTER, P.K. see ANKIER, S.I., 505 BOOBIS, A.R. see DAVIES, D.S., 89 CARROLL, J.A. see PEET, M., 212 BOUCHIER, I.A.D. see BATESON, M.C., 531 CASSANO, G.B. & CONTI, L. Some considerations on the BRADSHAW, C.M. see SZABADI, E., 416P role of benzodiazepines in the treatment of depression, BRAIBANTI, E. see MARTINI, A., 605 23S BRAITHWAITE, R.A. see TEDESCHI, G., 430P CASTLEDEN, C.M. see DONOVAN, M.A., 401 BRECKENRIDGE, A.M. see AWADZI, K., 418P CHADWICK, D., HAMPEL, G., HOLT, D.W. & VOL- BRECKENRIDGE, A.M. see BACK, D.J., 275 ANS, G.N. The absorption of conventional and BRECKENRIDGE, A.M. see CRAWFORD, FRANCESCA sustained-release mexiletine capsules in volunteer sub- E., 438P jects and patients, 1 16P BREUING, K.H. see JAHNCHEN, E.,.361 CHAMBERLAIN, J., HILL, H.M., INGS, R.M.J., BRODIE, M.J., BOOBIS, A.R., HILLYARD, C.J., McEWEN, J. & STONIER, P.D. Diurnal variation of ABEYASEKERA, G., MACINTYRE, I. & PARK, clobazam kinetics in man, 436P B.K. Inhibition by isoniazid of vitamin D metabolism in CHAN, K., DAVISON, SUSAN C., DEHGHAN, A. & man, 422P HYMAN, N. Clinical response and plasma levels of BRODIE, M.J. see BOOBIS, A.R., 419P pyridostigmine in myasthenic patients, 435P BRODIE, M.J. see DAVIES, D.S., 89 CHAN, K. see CALVEY, T.N., 124P BRODIE, M.J. see JENNER, D.A., 435P CHAN, K. see CALVEY, T.N., 406 BROWN, M.J. & DOLLERY, C.T. A specific radioen- CHAPUT DE SAINTONGE, D.M. see HONG, C.Y., 385 zymatic assay for dihydroxyphenylalanine (DOPA). CHARLES, B.G., RENSHAW, P.J., KAY, J.J. & Plasma DOPA may be the precursor of urine free RAVENSCROFT, P.J. Effect of metoclopramide on dopamine, 79 the bioavailability of long-acting propranolol, 5 17 INDEX 637

CHAUDHURY, R.R. see UPPAL, R., 522 DANESHMEND, T.K., HOMEIDA, M. & ROBERTS, CHECKLEY, S. see PETURSSON, H., 526 C.J.C. The effects of a combination of piretanide and CHOW, S.F. see LEE, P.K., 339 triamterene in healthy subjects, 106 CLANCY, A., STEINER, J.A., MANGHANI, K. & DANESHMEND, T.K., JACKSON, L. & ROBERTS, JAMES, I.M. Cardiovascular effects of SKF 92657, a C.J.C. Physiological and pharmacological variability in new antihypertensive agent with f-adrenoceptor an- estimated hepatic blood flow in man, 491 tagonist and vasodilator properties, 428P DARKE, A. see FUNG, H.-L., 579 CLARKE, A. see BATESON, M.C., 531 DAVIDSON, C. see CUMBERBATCH, M., 565 CLARKE, P. see SWIFT, C.G., 413P DAVIES, A.T. see BARNETT, D.B., 411P COATES, P.E. see HOLFORD, N.H.G., 187 DAVIES, D.S., KAHN, G.C., MURRAY, S., BRODIE, COCHET, B., BELAIEFF, J., ALLAZ, A.-F., M.J. & BOOBIS, A.R. Evidence for an enzymatic de- RUDHARDT, M., BALANT, L. & FABRE, J. De- fect in the 4-hydroxylation of debrisoquine by human creased extrarenal clearance of cefoperazone in liver, 89 hepatocellular diseases, 389 DAVIES, D.S. see BOOBIS, A.R., 419P COLE, J.O. see SCHATZBERG, A.F., 17S DAVISON, SUSAN C. see CHAN, K., 435P COLE, P. see TREMBATH, P.W., 19 DAY, J.M. & HOUSTON, J.B. Effect of ampicillin upon COLI, L. see STEFONI, S., 69 the availability of sulphapyridine following oral ad- COLLINS, J.V. see McALLISTER, W.A.C., 303 ministration of sulphasalazine in man, 423P COLTHART, D.J. see SALTISSI, S., 497 DEHGHAN, A. see CALVEY, T.N., 406 CONLON, C. see VANDENBURG, M.J., 485 DEHGHAN, A. see CHAN, K., 435P CONTI, L. see CASSANO, G.B., 23S DELUCCA, M.G. see FURLANUT, M., 393 COOK, P.J., CORLESS, D., CROME, P., FLANAGAN, DEPONDS, G. see BRUNNER, D.B., 461 R.J. & HUGGETT, A. Pharmacokinetics of DESAI, N. see BARNETT, D.B., 411P temazepam in volunteers and elderly hospital in- DETTLI, L. see HALLYNCK, TH., 523 patients, 123P DeVRIES, J. see STAIGER, CH., 214 COOK, P.J. see HARRIS, A., 93 DHILLON, SORAYA & RICHENS, A. Bioavailability COOPER, J.K. see MIDHA, K.K., 85 of rectally-administered diazepam in adult epileptic CORLESS, D. see COOK, P.J., 123P patients, 437P CRAWFORD, FRANCESCA E., BACK, D.J., ORME, DILBERIS, G. see FURLANUT, M., 393 M.L'E. & BRECKENRIDGE, A.M. The effect of DIVOLL, M. see GREENBLATT, D.J., 11S cigarette smoking on plasma concentrations of oral con- DIXON, A.St.J. see BENNETT, P.N., 110P traceptive steroids, 438P DJLANE, A. see HUGHES, R.J.D., 308 CROME, P., KIMBER, G.R., WAINSCOTT, G. & WID- DOERING, W. see FICHTL, B., 94 DOP, B. The effect of the simultaneous administration DOLLERY, C.T. see BROWN, M.J., 79 of oral metoclopramide on the absorption of DONOVAN, M.A., CASTLEDEN, C.M., POHL, J.E.F. & paracetamol in healthy volunteers, 430P KRAFT, C.A. The effect of age on digitoxin phar- CROME, P. see COOK, P.J., 123P macokinetics, 401 CROWTHER, A. see SALTISSI, S., 497 DORDAIN, G., PUECH, A.J. & SIMON, P. Triazolam, CRUICKSHANK, J.M. see NEIL-DWYER, G., 549 compared with nitrazepam and with oxazepam in insom- CULIG, J. see PLAVSIC, F., 533 nia: two double-blind, crossover studies analysed se- CUMBERBATCH, M., ZAREIAN, K., DAVIDSON, C., quentially, 43S MORGAN, D.B. & SWAMINATHAN, R. The early DRIESSEN, 0. see VAN DER VELDE, E.A., 41 and late effects of digoxin treatment on the sodium DUGAS, M. see TEDESCHI, G., 430P transport, sodium content and Na+K+-ATPase of DUNDEE, J.W., JONES, C.J. & MIRAKHUR, R.K. erythrocytes, 565 Comparison of glycopyrrolate given before or with CUNNINGHAM, J.L. & PRICE EVANS, D.A. neostigmine for reversal of residual neuromuscular Acetanilide and paracetamol pharmacokinetics before block, 417P and during phenytoin administration: genetic control of DZINDZIO, B.S. see UEDA, C.T., 571 induction?, 591

E D ECCLESTON, D. see ROWELL, F.J., 377 DAHLQVIST, RUNE see SCHENCK-GUSTAFSSON, EDMUNDS, L.C. see van der KLEUJN, E., 85S KARIN, 181 ELLIOTT, H.L. see CAMPBELL, B.C., 431P DALAL, J.J., ROSS, P.J., WONG, K., SHERIDAN, D.J., ELLIOTT, H.L. see CAP RUTTLEY, M.S.T., LEWIS, M.J. & HENDERSON, ELLIOTT, H.L., McLEAN, K., REID, J.L. & SUMNER, A.H. Acute effects of acebutolol and cardiovascular D.J. Pharmacodynamic studies on mianserin and its function in man, 265 interaction with clonidine, 122P DAMMANN, H.G. see STAIGER, CH., 214 ELLIS, A. see BACK, D.J., 275 DANEELS, R. see HALLYNCK, TH., 523 EL MEHAIRY, M.M., SHAKER, A., RAMADAN, M., DANESHMEND, T.K., FORD, J. & ROBERTS, C.J.C. HAMZA, S. & TADROS, S.S. Control of essential Variability in the enzyme inhibiting effect of cimetidine hypertension with captopril, an angiotensin converting in man, 421P enzyme inhibitor, 469 638 INDEX

F GUPTA, K.C. see SHETH, U.K., 251 GUSTAFSSON, L.L. see ALVAN, G., 625 FABRE, J. see COCHET, B., 389 FACCHINI, V. & TIMBRELL, J.A. Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man, 345 FAIRBAIRN, A.F. see ROWELL, F.J., 377 H FARROW, P.R. see THOM, S., 423P HA, H.R., KEWITZ, G., WENK, M. & FOLLATH, F. FERRARI, C. see BARBIERI, R., 314 Quinidine determination in serum: enzyme immuno- FERRIER, I.N. see JOHNSTONE, EVE C., 219 assay (EIA) v HPLC, 312 FIABANE, A.M. see BATESON, M.C., 531 HAATAJA, MATTI see AITIO, MIRJA-LIISA, 279 FICHTL, B. & DOERING, W. The digoxin-quinidine in- HADDOCK, D.R. see AWADZI, K., 418P teraction: serum protein binding unlikely to be involved, HADJ AISSA, A., POZET, N., LABEEUW, M., PEL- 94 LET, M. & TRAEGER, J. Acute effect of a high dose FINCHAM, N. see BLACK, A.K., 109P (48 mg) of piretanide in advanced renal insufficiency, 63 FLANAGAN, R.J. see COOK, P.J., 123P HALL, J.M. see BACK, D.J., 275 FOLLATH, F. see HA, H.R., 312 HALL, R.C.W. & ZISOOK, S. Paradoxical reactions to FORD, J. see DANESHMEND, T.K., 421P benzodiazepines, 99S FRASER, H.S. Clinical pharmacology in developing coun- HALLYNCK, TH., SOEP, H.H., THOMIS, J.A., tries, 457 BOELAERT, J., DANEELS, R. & DETTLI, L. Should FREEMONT, A.J. see BARNETT, D.B., 432P clearance be normalized to body surface or to lean body FREESTONE, S. & RAMSAY, L.E. Effect of coffee and mass?, 523 cigarette smoking in untreated and diuretic-treated HAMER, J., JOHNSTON, A., BURGESS, C. & hypertensive patients, 428P TURNER, P. The biological availability of oral ver- FUNG, H.-L., McNIFF, E.F., RUGGIRELLO, D., apamil, evidence that the metabolites are inactive, 426P DARKE, A., THADANI, U. & PARKER, J.O. Kine- HAMER, J. see WEERASURIYA, K., 398 tics of isosorbide dinitrate and relationships to phar- HAMPEL, G. see CHADWICK, D., 116P macological effects, 579 HAMZA, S. see EL MEHAIRY, M.M., 469 FURLANUT, M., DELUCCA, M.G., DILBERIS, G. & HANKS, G.W. see BLOOMFIELD, S.S., 98 BARNABA, A. Rapid and sensitive high-pressure HANSSON, B.G. & HOKFELT, B. Changes in blood liquid chromatographic method for monitoring pressure, plasma catecholamines and plasma renin ac- carbamazepine levels in serum, 393 tivity during and after treatment with tiamenidine and clonidine, 73 HARMATZ, J.S. see GREENBLATT, D.J., i1S G HARMATZ, J.S. see GREENBLATT, D.J., 35 HARRIS, A., COOK, P.J., JEWELL, D.P. & JAMES, I.M. GAMBLE, S.J. see JOSEPH, M.H., 414P Cimetidine and cerebral blood flow in elderly patients, GANESAN ADAIKAN, P. see KARIM, S.M.M., 99 93 GARG, S.K. see UPPAL, R., 522 HARRIS, M.J. see JOSEPH, M.H., 414P GASZNER, P. see SZABADI, E., 416P HARRISON, I.R., McINNES, G.T., PERKINS, R.M. & GELDER, M.G. see ORR, M.W., 255 SHELTON, J.R. (introduced by GOLDBERG, A.). GEORGE, A.J. & WILSON, K.C.M. Puerperal mood Bioassay in healthy men and therapeutic potency of changes and platelet monoamine oxidase activity, 41 SP aldosterone antagonists, 426P GHOSE, KARABI (introduced by TURNER, P.). Biologi- HARRISON, I.R. see McINNES, G.T., 114P cal half-life of amitriptyline, 122P HARRON, D.W.G., RIDDELL, J.G. & SHANKS, R.G. GILFRICH, H.J. see JAHNCHEN, E., 361 Cardiovascular effects of alinidine (ST567) in healthy GILLIES, H.M. see AWADZI, K., 418P volunteers, 116P GOLDBERG, A. see HARRISON, I.R., 426P HARRON, D.W.G. & SHANKS, R.G. Comparison of the GOLDBERG, A. see McINNES, G.T., 114P duration of effect of metoprolol and a sustained release GOLDSWORTHY, S.J. & KEMP, M. (introduced by formulation of metoprolol (Betaloc-SA), 518 MORLEY, J.). Salivary and urine theophylline levels in HARRON, D.W.G. see BALNAVE, K., 171 the management of childhood asthma, 434P HATHWAY, N.R. see SHARMA, J.N., 433P GRAHAM, C. see ANKIER, S.I., 505 HAWKSWORTH, G.M. see BARBER, H.E., 118P GRAHAME-SMITH, D.G. see ORR, M.W., 255 HAWKSWORTH, G.M. see WEBSTER, J., 333 GREAVES, M.W. see BLACK, A.K., 109P HAYTHORNE, J.M. see SWIFT, C.G., 413P GREENBLATT, D.J., LAUGHREN, T.P., ALLEN, HEDGES, A. see LIMA, D.R.A., 555 MARCIA D., HARMATZ, J.S. & SHADER, R.I. HENDERSON, A.H. see DALAL, J.J., 265 Plasma diazepam and desmethyldiazepam concentra- HENRY, J.A. & MITCHELL, S.N. (introduced by tions during long-term diazepam therapy, 35 TURNER, P.). Effect of pH on human plasma protein GREENBLATT, D.J., SHADER, R.I., DIVOLL, M. & binding of a series of P-adrenoceptor antagonists, 119P HARMATZ, J.S. Benzodiazepines: a summary of phar- HENRY, J.F. see TEDESCHI, G., 430P macokinetic properties, 1 IS HENSBY, C.N. see BLACK, A.K., 109P GREENBLATT, D.J. see SHADER, R.I., SS HETTIARCHCHI, J. see RAMSEY, L.E., 153 GRIFFITHS, R. see WEBSTER, H.E., 333 HILL, H.M. see CHAMBERLAIN, J., 436P GUENTERT, T.W. see HOLFORD, N.H.G., 187 HILLYARD, C.J. see BRODIE, M.J., 422P INDEX 639

HODDER, R.W. see BROWN, K., 425P JAMES, I.M. see MAIDMENT, C.G., 310 HOKFELT, B. see HANSSON, B.G., 73 JAUERNIG, R.A. see MOULDS, R.F.W., 57 HOLFORD, N.H.G., COATES, P.E., GUENTERT, JEFFERS, T.A. see WEBSTER, J., 333 T.W., RIEGELMAN, S. & SCHEINER, L.B. The ef- JENKINS, C.R. & MARLIN, G.E. The metabolic actions fect of quinidine and its metabolites on the electrocar- of intravenous salbutamol and aminophylline singly and diogram and systolic time intervals: concentration- in combination, 197 effect relationships, 187 JENNER, D.A. & BROWN, M.J. (introduced by HOLLISTER, L.E. Benzodiazepines - an overview, 117S BRODIE, M.J.). Simultaneous determination of en- HOLT, D.W. see CHADWICK, D., 116P dogenous catecholamines, a-methyldopa and a- HOLT, J.E. see KAYE, C.M., 395 methylnoradrenaline in plasma, using HPLC with elec- HOLT, H.A. see REEVES, D.S., 353 trochemical detection, 435P HOMEIDA, M. see DANESHMEND, T.K., 106 JEWELL, D.P. see HARRIS, A., 93 HONG, C.Y., CHAPUT DE SAINTONGE, D.M. & JOHNSTON, A. see HAMER, J., 426P TURNER, P. A simple method to measure drug effects JOHNSTON, A. see SHARMA, J.N., 433P on human sperm motility, 385 JOHNSTONE, EVE C. & FERRIER, I.N. Neural mechan- HORAI, Y. see TSUJIMOTO, G., 622 isms controlling the secretion of corticotrophin releasing HOUSTON, J.B. see DAY, J.M., 423P factor, 219 HUBBARD, J.W. see MIDHA, K.K., 85 JOHNSTONE, EVE C. see JOSEPH, M.H., 414P HUGGETT, A. see COOK, P.J., 123P JOHNSTON, G.D. see TAGGART, A.J., 31 HUGHES, M.A., MACKIE, R.M., MEREDITH, P.A. & JONES, C.J. see DUNDEE, J.W., 417P NELSON, H.M. (introduced by REID, J.L.). The kine- JONES, MIRANDA M.C., NICHOLSON, A.N. & tics of 8-methoxypsoralen and the response to PUVA in STONE, BARBARA M. Studies with the heterocyclic patients with dermatological diseases, 424P amphetamine derivatives, prolintane and pemoline, on HUGHES, M.A. see CAMPBELL, B.C., 431P sleep in man, 123P HUGHES, R. see PAYNE, J.P., 537 JOSEPH, M.H., GAMBLE, S.J., HARRIS, M.J., JOHN- HUGHES, R.D.J. see MAIDMENT, C.G., 310 STONE, EVE C. & RISBY, D. The availability of HUGHES, R.J.D., JAMES, I.M. & DJLANE, A. The effect tryptophan after loading in patients with depression or of betahistine methanesulphonate upon cerebral blood schizophrenia, 414P flow, 308 HUI, S.M. see ROWELL, F.J., 377 HUSTON, G.J. Local buccal mucosal effects of aspirin, indomethacin and isoxepac; their relationship to gas- trointestinal damage, 528 K HYMAN, N. see CHAN, K., 435P KAHN, G.C. see BOOBIS, A.R., 419P KAHN, G.C. see DAVIES, D.S., 89 KANTO, J., ALLONEN, H., JALONEN, H. & MANTY- LA, R. The effect of metoclopramide and propantheline I on the gastrointestinal absorption of cimetidine, 629 IDLE, J.R., OATES, N.S., SHAH, R.R. & SMITH, R.L. Is KAPETANOVIC, I.M., KUPFERBERG, H.J., THEO- there a genetic predisposition to phenformin-induced DORE, W. & PORTER, R.J. Lack of effect of valproate lactic acidosis?, 418P on paracetamol (acetaminophen) disposition in epilep- ILETT, K.F. see PATERSON, J.W., 387 tic patients, 391 INGS, R.M.J. see CHAMBERLAIN, J., 436P KARIM, S.M.M., GANESAN ADAIKAN, P. & KOT- ISHIZAKI, T. see TSUJIMOTO, G., 622 TEGODA, S.R. Effect of pregnenolone-16a- 622 carbonitrile (PCN) on bilirubin clearance in man, 99 ITOH, K., see TSUJIMOTO, G., KATHER, H. see STAIGER, CH., 214 KAY, D.C., PICKWORTH, W.B. & NEIDERT, G.L. Morphine-like insomnia from heroin in non-dependent J human addicts, 159 KAY, J.J. see CHARLES, B.G., 517 JACK, D.B. Is there a relationship between the physical KAYE, C.M., SANKEY, M.G. & HOLT, J.E. A high- properties and cardioselectivity of 0-adrenoceptor an- pressure liquid chromotographic method for the assay of tagonists?, 402 ketoprofen in plasma and urine, and its application JACK, D.B. see QUARTERMAN, C.P., 287 to determining the urinary excretion of free and con- JACK, D.B. see ROBERTS, D.H., 561 jugated ketoprofen following oral administration of JACKSON, L. see DANESHMEND, T.K., 491 Orudis® to man, 395 JAHNCHEN, E., BLANCK, K.J., BREUING, K.H., GIL- KELLER, I. see BRUNNER, D.B., 461 FRICH, H.J., MEINERTZ, T. & TRENK, D. Plasma KEMP, M. see GOLDSWORTHY, S.J., 434P protein binding of azapropazone in patients with kidney KENDALL, M.J. see QUARTERMAN, C.P., 287 and liver disease, 361 KENDALL, M.J. see ROBERTS, D.H., 561 JAKOBSEN, P. see PEDERSEN, A. KIRSTEIN, 597 KEWITZ, G. see HA, H.R., 312 JALONEN, H. see KANTO, J., 629 KILFEATHER, S. see LIMA, D.R.A., 120P JAMES, I.M. see CLANCY, A., 428P KILFEATHER, S. see LIMA, D.R.A., 215 JAMES, I.M. see HARRIS, A., 93 KILFEATHER, S. see LIMA, D.R.A., 555 JAMES, I.M. see HUGHES, R.J.D., 308 KIMBER, G.R. see CROME, P., 430P 640 INDEX

KINNEY, C.D. see SALEM, S.A.M., 412P LLOYD, D. see B1TTENCOURT, P., 437P KITCHELL, W.W. see ROUTLEDGE, P.A., 245 LOK, A.S.F. see LEE, P.K., 339 van der KLEUN, E., VREE, T.B., BAARS, A.M., WISJ- LORENZI, MARA see WHITING, B., 295 MAN, R., EDMUNDS, L.C. & KNOP, H.J. Factors influencing the activity and fate of benzodiazepines in the body, 85S KNAPP, M.S. see KOWANKO, I.C., 477 Mc KNOP, H.J. see van der KLEUN, E., 85S McAINSH, J. see NEIL-DWYER, G., 549 KNOX, J.M., ORR, M.W., ALLEN, R., GELDER, M.G. McALLISTER, W.A.C., MITCHELL, D.M. & COLLINS, & GRAHAME-SMITH, D.G. The reliability of 5- J.V. Prednisolone pharmacokinetics compared between hydroxytryptamine induced platelet aggregation re- night and day in asthmatic and normal subjects, 303 sponses in schizophrenic patients treated with neurolep- McDEVlTT, D.G. see SALEM, S.A.M., 412P tic drugs, 261 McDEVITT, D.G. see TAGGART, A.J., 31 KNOX, J.M. see ORR, M.W., 255 McEWEN, J. see CHAMBERLAIN, J., 436P KOTTEGODA, S.R. see KARIM, S.M.M., 99 McINNES, G.T. see HARRISON, I.R., 426P KOWANKO, I.C., POWNALL, R., KNAPP, M.S., McINNES, G.T., SHELTON, J.R. & HARRISON, I.R. SWANNELL, A.J. & MAHONEY, P.G.C. Circadian (introduced by GOLDBERG, A.). The potency of pro- variations in the signs and symptoms of rheumatoid renoate potassium relative to spironolactone at steady- arthritis and in the therapeutic effectiveness of flurbi- state in man, 114P profen at different times of day, 477 MACINTYRE, I. see BRODIE, M.J., 422P KRAFT, C.A. see DONOVAN, M.A., 401 MACIVER, M. see BACK, D.J., 275 KRAMER, M.S. Difficulties in assessing the adverse effects MACKAY, A.V.P. Assessment of anti-psychotic drugs, of drugs, 105S 225 KULKARNI, V.M. see SHETH, U.K., 251 MACKENZIE, J.E. see PARRATT, J.R., 307 KUPFERBERG, H.J. see KAPETANOVIC, I.M., 391 MACKIE, R.M. see HUGHES, M.A., 424P MACKONKA, CINDY see MIDHA, K.K., 85 McLEAN, K. see CAMPBELL, B.C., 431P L McLEAN, K. see ELLIOTT, H.L., 122P MACLEOD, N. Triazolam: monitored release in the LABEEUW, M. see HADJ AISSA, A., 63 United Kingdom, 51 S LADER, M. The clinical assessment of depression, S McNIFF, E.F. see FUNG, H.-L., 579 LADER, M.H. see PETURSSON, H., 526 LAI, C.L. see LEE, P.K., 339 LAI, K.N. see LEE, P.K., 339 LAM, K.C. see LEE, P.K., 339 M LASAGNA, L. Bias in the elucidation of subjective side- effects, 11lS MADDISON, STEPHANIE, E. see BHATT, ASHA M., LAUGHREN, T.P. see GREENBLATT, D.J., 35 209 LAWRENCE, J.R. see BAIRD, G.M., 112P MADSEN, B.W., MURPHY, B.P. & TARALA, R.A. LAWTON, D.J. see SIMPSON, R.J., 96 Maximum or mean FEV1 for bronchodilator aerosol LAZDA, E. see VANDENBURG, M., 105 evaluation in acute asthmatics, 631 LEAHY, W.J. see BALNAVE, K., 171 MAHONEY, P.G.C. see KOWANKO, I.C., 477 LEDINGHAM, J.M. see VANDENBURG, M.J., 485 MAIDMENT, C.G., HUGHES, R.D.J. & JAMES, I.M. LEE, P.K., LAI, C.L., LOK, A.S.F., TSE, T.F., LAI, K.N., The effects of intravenous disopyramide on cerebral CHOW, S.F. & LAM, K.C. Haemodynamic responses blood flow in volunteers, 310 to intravenous cimetidine in subjects with normal lung MANGHANI, K. see CLANCY, A., 428P function and in subjects with chronic airway obstruction, MANSBURY, LEENA see AITIO, MIRJA-LIISA, 279 339 MANTYLA, R. see KANTO, J., 629 LEWIS, M.J. see DALAL, J.J., 265 MARLIN, G.E. see JENKINS, C.R., 197 LIMA, D.R.A., KILFEATHER, S., HEDGES, A. & MARSDEN, C.D. & SCHACHTER, M. Assessment of TURNER, P. Comparison of four different P- extrapyramidal disorders, 129 adrenoceptor blocking drugs on lymphocyte MARTIN, B.K. see ANKIER, S.I., 505 isoprenaline-stimulated cyclic AMP production, 555 MARTINI, A., BONOLLO, L., NICOLIS, F.B., SEGA, R. LIMA, D.R.A., KILFEATHER, S. & TURNER, P. Lym- & PALERMO, A. Effects of caroxazone, a reversible phocyte cyclic AMP in hypertensive patients treated monoamine oxidase inhibitor, on the pressor response with P-adrenoceptor blocking drugs, 120P to oral tyramine in man, 611 LIMA, D.R.A. & TURNER, P. Partial agonist activity of MARTINI, A., BONOLLO, L., NICOLIS, F.B., SEGA, practolol on human lymphocyte cyclic AMP production, R., PALERMO, A. & BRAIBANTI, E. Effects of 521 caroxazone, a reversible monoamine oxidase inhibitor, LIMA, D.R.A., THROWER, P., KILFEATHER, S., on the pressor response to intravenous tyramine in man, O'GRADY, J. & TURNER, P. Influence of pH on the 605 in vitro activity of prostacyclin on human lymphocyte MARTINI, A. see MORETTI, A., 511 cyclic AMP production, 215 MATHER, L.E. see AUSTIN, K.L., 25 LrITLEJOHNS, D.W. & VERE, D.W. The clinical assess- MAXWELL, C. Clinical trials, reviews, and the joumal of ment of analgesic drugs, 319 negative results, 15 INDEX 641

MEINERTZ, T. see JAHNCHEN, E., 361 NICHOLSON, A.N. see CANNINGS, R., 410P MEREDITH, P.A. see BARCLAY, JOYCE, 203 NICHOLSON, A.N. see JONES, MIRANDA M.C., 123P MEREDITH, P.A. see CAMPBELL, B.C., 431P NICOLELLA, V. see MORETTI, A., 511 MEREDITH, P.A. see HUGHES, M.A., 424P NICOLIS, F.B. see MARTINI, A., 605 MIDDLEMISS, D.N. see PEET, M., 212 NICOLIS, F.B. see MARTINI, A., 611 MIDHA, K.K., MACKONKA, CINDY, COOPER, J.K., NICOLIS, F.B. see MORETTI, A., 511 HUBBARD, J.W. & YEUNG, P.K.F. Radioim- NOTARIANNI, LIDIA J. see BENNETT, P.N., 1l0P munoassay for perphenazine in human plasma, 85 MIKULIC, E. see TEDESCHI, G., 430P MILLIGAN, N. & RICHENS, A. Methods of assessment of antiepileptic drugs, 443 0 MILNE, L.A. see CALVEY, T.N., 124P MIRAKHUR, R.K. see DUNDEE, J.W., 417P OATES, N.S. see IDLE, J.R., 418P MITCHELL, D.M. see McALLISTER, W.A.C., 303 O'GRADY, J. see LIMA, D.R.A., 215 MITCHELL, K. see MOHAMMED, R., 408 OLDHAM, HARRIET G. see BENNETT, P.N., 1 10P MITCHELL, S.N. see HENRY, J.A., 119P O'MALLEY, B.P. see BARNETT, D.B., 432P MOHAMMED, R. & MITCHELL, K. The effect of ORME, M.L'E. see AWADZI, K., 418P ranitidine, a new histamine H2-receptor antagonist, on ORME, M.L'E. see BACK, D.J., 275 the amylase/creatinine clearance ratio, 408 ORME, M.L'E. see CRAWFORD, FRANCESCA E., MOODY, J.P., SMITH, A.H.W. & NAYLOR, G.J. The 438P effect of mianserin on urinary catecholamine excretion ORR, M.W., KNOX, J.M., ALLEN, R., GELDER, M.G. in psychiatric patients, 103 & GRAHAME-SMITH, D.G. The effects of neurolep- MORELAND, T.A., PARK, B.K. & RYLANCE, G.W. tic drugs on 5-hydroxytryptamine induced platelet ag- Drug metabolizing enzyme induction in children, 420P gregation in schizophrenic patients, 255 MORELAND, T.A., RYLANCE, G.W. & STEVENSON, OWENS, E.L. see BAKER, J.R., 305 I.H. Dichloralphenazone elimination as an index of drug metabolizing ability in children, 111P MORETTI, A., CACCIA, C., MARTINI, A., BONOLLO, p L., AMICO, A., SEGA, R., NICOLELLA, V. & NICOLIS, F.B. Effect of caroxazone, a new antidepres- PALERMO, A. see MARTINI, A., 605 sant drug, on monoamine oxidases in healthy volun- PALERMO, A. see MARTINI, A., 611 teers, 511 PARFREY, P. see VANDENBURG, M., 105 MORGAN, D.B. see CUMBERBATCH, M., 565 PARK, B.K. see BRODIE, M.J., 422P MORLEY, J. see GOLDSWORTHY, S.J., 434P PARK, B.K. see MORELAND, T.A., 420P MORSELLI, P.L. see TEDESCHI, G., 430P PARKER, J.O. see FUNG, H.-L., 579 MOSCONI, G. see STEFONI, S., 69 PARRATT, J.R. & MACKENZIE, J.E. Possible mechan- MOULDS, R.F.W., JAUERNIG, R.A. & SHAW, J. A isms of action of oxyfedrine as an antianginal drug, 307 comparison of the effects of hydrallazine, diazoxide, PASCOE, PETA A. see NICHOLSON, A.N., 123P sodium nitrite and sodium nitroprusside on human iso- PATEL, LATA see BARBAT, J., 117P lated arteries and veins, 57 PATERSON, J.W. & ILETT, K.F. Oral sustained-release MOWAT, N.A.G. see WEBSTER, H.E., 333 aminophylline in medical inpatients, 387 MURPHY, B.P. see MADSEN, B.W., 631 PAYNE, J.P. & HUGHES, R. Clinical assessment of MURRAY, G.R. see CALVEY, T.N., 124P neuromuscular transmission, 537 MURRAY, S. see BOOBIS, A.R., 419P PECK, C.C. see BAKER, J.R., 305 MURRAY, S. see DAVIES, D.S., 89 PEDERSEN, A. KIRSTEIN & JAKOBSEN, P. Sulphin- pyrazone metabolism during long-term therapy, 597 PEET, M., YATES, R.A., CARROLL, J.A. & MIDDLEMISS, D.N. The interaction of tyramine with N a single dose of tranylcypromine in healthy volunteers, 212 NAYLOR, G.J. see MOODY, J.P., 103 PELLET, M. see HADJ AISSA, A., 63 NEALE, M.G. see BROWN, K., 425P PENNY, W.J., RHODES, J. & THOMPSON, W. Protec- NEIDERT, G.L. see KAY, D.C., 159 tion against aspirin-induced blood loss in man: assess- NEIL-DWYER, G., BARTLETT, J., McAINSH, J. & ment of a new mucolytic agent, 626 CRUICKSHANK, J.M. 0-adrenoceptor blockers and PERKINS, R.M. see HARRISON, I.R., 426P the blood-brain barrier, 549 PERUCCA, E., RICHENS, A. & RUPRAH, M. Serum NEILL, J.D. see BALNAVE, K., 171 protein binding of phenytoin in pregnant women, 409P NELSON, H.M. see HUGHES, M.A., 424P PETERSEN, J. see BARBER, H.E., 1 13P NEMETH, I. & SZELECZKI, T. Enhanced drug metabol- PETERSEN, J. see WEBSTER, J., 333 ism and renal dysfunction, 92 PETRIE, J.C. see BARBER, H.E., 118P NICHOLSON, A.N. The use of short- and long-acting PETRIE, J.C. see WEBSTER, J., 333 hypnotics in clinical medicine, 61S PETURSSON, H., SHUR, E., CHECKLEY, S., SLADE, NICHOLSON, A.N., PASCOE, PETA A. & STONE, A. & LADER, M.H. A neuroendocrine approach to BARBARA M. Efficacy of some benzodiazepines for benzodiazepine tolerance and dependence, 526 day-time sleep, 123P PEUCH, A.J. see DORDAIN, G., 43S 642 INDEX

PICKWORTH, W.B. see KAY, D.C., 159 RIDDELL, J.G. see HARRON, D.W.G., 116P PISPATI, P.K. see SHETH, U.K., 251 RIEGELMAN, S. see HOLFORD, N.H.G., 187 PLAVSIC, F., CULIG, J., BAKRAN, I. Jr & VRHOVAC, RIGBY, J.W. see BARBER, H.E., 118P B. Theophylline concentration in saliva as a guide for RISBY, D. see JOSEPH, M.H., 414P individualization of its therapeutic use, 533 RIVA, R. see TEDESCHI, G., 618 PLEUVRY, BARBARA J. see BHATT, ASHA M., 209 ROBB, O.J. see BARBER, H.E., 118P POHL, J.E.F. see DONOVAN, M.A., 401 ROBERTS, C.J.C. see DANESHMEND, T.K., 106 PORTER, R.J. see KAPETANOVIC, I.M., 391 ROBERTS, C.J.C. see DANESHMEND, T.K., 421P POWNALL, R. see KOWANKO, I.C., 477 ROBERTS, C.J.C. see DANESHMEND, T.D., 491 POZET, N. see HADJ AISSA, A., 63 ROBERTS, D.H., KENDALL, M.J., JACK, D.B. & PRANDINI, R. see STEFONI, S., 69 WELLING, P.G. Pharmacokinetics of cephradine given PRICE EVANS, D.A. see CUNNINGHAM, J.L., 591 intravenously with and without probenecid, 561 Proceedings of a symposium entitled 'Benzodiazepines - a ROBERTS, M. see TREMBATH, P.W., 19 clinical review', 1S- 120S ROBINS, D.S. see WHITING, B., 295 Proceedings of the British Pharmacological Society, Uni- ROBSON, R.A., TAYLOR, B.J. & TAYLOR, B. Sodium versity of Aberdeen, 10-12 September, 1980 (Joint cromoglycate: spincaps or metered dose aerosol, 383 meeting with the Societe Belge de Physiologie et de ROGERS, H.J. see AHMAD, R.A., 101 Pharmacologie), 109P-126P ROGERS, M.S. see ANKIER, S.I., 505 Proceedings of the British Pharmacological Society, Uni- ROSS, P.J. see DALAL, J.J., 265 versity of London, 16-18 December, 1980, 409P-439P ROSSENEU, M. see BELPAIRE, F.M., 125P PURPURA, R.P. Approaches in the evaluation of hypno- ROTH, T., ZORICK, F., SICKLESTEEL, JEANNE & tics: studies with triazolam, 37S STEPANSKI, E. Effects of benzodiazepines on sleep and wakefulness, 31S ROUTLEDGE, P.A., STARGEL, W.W., KITCHELL, Q B.B., BARCHOWSKY, A. & SHAND, D.G. Sex- related differences in the plasma protein binding of QUARTERMAN, C.P., KENDALL, M.J. & JACK, D.B. lignocaine and diazepam, 245 The effect of age on the pharmacokinetics of metoprolol ROWE, P.H. see BACK, D.J., 275 and its metabolites, 287 ROWELL, F.J., HUI, S.M., FAIRBAIRN, A.F. & EC- CLESTON, D. Total and free serum haloperidol levels in schizophrenic patients and the effect of age, R thioridazine and fatty acid on haloperidol-serum protein binding in vitro, 377 RAMADAN, M. see EL MEHAIRY, M.M., 469 RUBIN, P.C. Clinical pharmacology of prazosin, 222 RAMSAY, L.E. Oral sustained-release aminophylline in RUBIN, P.C., SCOTT, P.J.W. & REID, J.L. The influence medical inpatients, 388 of age on prazosin disposition, 427P RAMSEY, L.E. & HETTIARCHCHI, J. Spironolactone in RUDHARDT, M. see COCHET, B., 389 thiazide-induced hypokalaemia: variable response be- RUGGIRELLO, D. see FUNG, H.-L., 579 tween patients, 153 RUPRAH, M. see PERUCCA, E., 409P RAMSAY, L.E. see FREESTONE, S., 428P RUSSELL, C.J. see BALNAVE, K., 171 RAVENSCROFT, P.G. see CHARLES, B.G., 517 RUTTLEY, M.S.T. see DALAL, J.J., 265 RAWLINS, M.D. & SEYMOUR, R.A. The analgesic ef- RYLANCE, G.W. see MORELAND, T.A., 11 IP fect of paracetamol in post-operative dental pain, 1 23P RYLANCE, G.W. see MORELAND, T.A., 420P RAWLINS, M.D. see BATEMAN, D.N., 221 RAWLINS, M.D. see THOM, S., 423P RAYBUCK, B.D. see BAKER, J.R., 305 S REEVES, D.S., BULLOCK, D.W., BYWATER, M.J., HOLT, H.A., WHITE, L.O. & THORNHILL, D.P. SALEM, S.A.M., KINNEY, C.D. & McDEVITT, D.G. The effect of probenecid on the pharmacokinetics and Pharmacokinetics and psychomotor effects of nit- distribution of cefoxitin in healthy volunteers, 353 razepam and temazepam in young males and females, REID, J.L. see CAMPBELL, B.C., 121P 412P REID, J.L. see CAMPBELL, B.C., 431P SALTISSI, S., CROWTHER, A., BYRNE, C. & COL- REID, J.L. see ELLIOTT, H.L., 122P THART, D.J. The effects of chronic oral cimetidine REID, J.L. see HUGHES, M.A., 424P therapy on the cardiovascular system in man, 497 REID, J.L. see RUBIN, P.C., 427P SANKEY, M.G. see KAYE, C.M., 395 RENSHAW, P.J. see CHARLES, B.G., 517 SANTOSO, B. see THOM, S., 423P RHODES, J. see ALBAN DAVIES, H., 53 SCHACHTER, M. see MARSDEN, C.D., 129 RHODES, J. see PENNY, W.J., 626 SCHATZBERG, A.F. & COLE, J.O. Benzodiazepines in RICHENS, A. Editorial, 3 the treatment of depressive, borderline personality, and RICHENS, A. see B1TTENCOURT, P., 437P schizophrenic disorders, 17S RICHENS, A. see DHILLON, SORAYA, 437P SCHELLING, J.L. see BRUNNER, D.B., 461 RICHENS, A. see MILLIGAN, N., 443 SCHENCK-GUSTAFSSON, KARIN & DAHLQVIST, RICHENS, A. see PERUCCA, E., 409P RUNE. Pharmacokinetics of digoxin in patients sub- RICKELS, K. Are benzodiazepines overused and abused?, jected to the quinidine-digoxin interaction, 181 71S SCHUSTER, B.G. see BAKER, J.R., 305 INDEX 64 3

SCOTIT, A.K. see BARBER, H.E., 1 18P STONIER, P.D. see CHAMBERLAIN, J., 436P SCOTT, P.J.W. see RUBIN, P.C., 427P SUMNER, D.J. see ELLIOTT, H.L., 122P SEGA, R. see MARTINI, A., 605 SWAMINATHAN, R. see CUMBERBATCH, M., 565 SEGA, R. see MARTINI, A., 611 SWANNELL, A.J. see KOWANKO, I.C., 477 SEGA, R. see MORETTI, A., 511 SWIFT, C.G., HAYTHORNE, J.M., CLARKE, P. & SEYMOUR, R.A. see RAWLINS, M.D., 123P STEVENSON, I.H. The effect of ageing on measured SHADER, R.I. Benzodiazepines in clinical medicine: dis- responses to single doses of oral temazepam, 413P cussion, 55S SZABADI, E., GASZNER, P. & BRADSHAW, C.M. An SHADER, R.I. & GREENBLATT, D.J. The use of ben- investigation of the a-adrenoceptor blocking properties zodiazepines in clinical practice, SS of neuroleptics in the human iris in vivo, 416P SHADER, R.I. see GREENBLATT, D.J., 11S SZELECZKI, T. see NEMETH, I., 92 SHADER, R.I. see GREENBLATT, D.J., 35 SHAH, R.R. see IDLE, J.R., 418P SHAKER, A. see EL MEHAIRY, M.M., 469 SHAND, D.G. see ROUTLEDGE, P.A., 245 T SHANKS, R.G. see BALNAVE, K., 171 SHANKS, R.G. see HARRON, D.W.G., 116P TADROS, S.S. see EL MEHAIRY, M.M., 469 SHANKS, R.G. see HARRON, D.W.G., 518 TAGGART, A.J., JOHNSTON, G.D. & McDEVITT, SHARMA, J.N., JOHNSTON, A., BLACKETT, A.N. & D.G. Does the frequency of daily dosage influence HATHWAY, N.R. (introduced by TURNER, P.). compliance with digoxin therapy?, 31 Comparative bioavailability of some sustained release TALA, EERO see AITIO, MIRJA-LIISA, 279 theophylline preparations in normal volunteers, 433P TARALA, R.A. see MADSEN, B.W., 631 SHARMA, P.R. see UPPAL, R., 522 TAYLOR, B. see ROBSON, R.A., 383 SHAW, J. see MOULDS, R.F.W., 57 TAYLOR, B.J. see ROBSON, R.A., 383 SHEINER, L.B. see HOLFORD, N.H.G., 187 TAYLOR, E.A. see TREMBATH, P.W., 19 SHELTON, J.R. see HARRISON, I.R., 426P TEDESCHI, G., BIANCHETTI, G., HENRY, J.F., SHELTON, J.R. see McINNES, G.T., 114P BRAITHWAITE, R.A., MIKULIC, E., DUGAS, M. SHEPHERD, A.N. see CAMPBELL, B.C., 121P & MORSELLI, P.L. Influence of age and disease states SHERIDAN, D.J. see DALAL, J.J., 265 on the plasma protein binding of haloperidol, 430P SHETH, U.K., VALAME, S.P., GUPTA, K.C., BAXI, TEDESCHI, G., RIVA, R. & BARUZZI, A. Clobazam A.J., KULKARNI, V.M. & PISPATI, P.K. Tolerability plasma concentrations: pharmacokinetic study in heal- of ibuprofen and flurbiprofen in G-6-PD deficient sub- thy volunteers and data in epileptic patients, 618 jects: in vitro study, 251 TEIRLYNCK, 0. see BELPAIRE, F.M., 125P SHUR, E. see PETURSSON, H., 526 THADANI, U. see FUNG, H.-L., 579 SICKLESTEEL, JEANNE, see ROTH, T., 31S THEODORE, W. see KAPETANOVIC, I.M., 391 SIMON, B. see STAIGER, CH., 214 THOM, S., FARROW, P.R., SANTOSO, B., ALBERTI, SIMON, P. Evaluation of side-effects and handling of data: K.G.M.M. & RAWLINS, M.D. Effects of oral glucose discussion, 115S in lime juice on isoniazid kinetics, 423P SIMON, P. see DORDAIN, G., 43S THOMAS, M. see ALBAN DAVIES, H., 53 SIMPSON, R.J., LAWTON, D.J., WATT, M.H. & TI- THOMIS, J.A. see HALLYNCK, TH., 523 PLADY, B. Effect of zimelidine, a new antidepressant, THOMPSON, W. see PENNY, W.J., 626 on appetite and body weight, 96 THORNHILL, D.P. see REEVES, D.S., 353 SLADE, A. see PETURSSON, H., 526 THROWER, P. see LIMA, D.R.A., 215 SMITH, A.H.W. see MOODY, J.P., 103 TIMBRELL, J.A. see FACCHINI, V., 345 SMITH, A.T. see BITTENCOURT, P., 437P TIPLADY, B. A basic program for constructing a dispens- SMITH, R.L. see IDLE, J.R., 418P ing list for a randomized clinical trial, 617 SOEP, H.H. see HALLYNCK, TH., 523 TIPLADY, B. see SIMPSON, R.J., 96 STAIGER, CH., SIMON, B., DeBRIES, J., KATHER, H., TOSELAND, P.A. see BITTENCOURT, P., 437P DAMMANN, H.G. & WALTER, E. Comparative ef- TOVERUD, E.-L. see BOOBIS, A.R., 419P fects of ICI 125,211 and cimetidine on antipyrine TRAEGER, J. see HADJ AISSA, A., 63 kinetics, 214 TREMBATH, P.W., TAYLOR, E.A., TURNER, P., STARGEL, W.W. see ROUTLEDGE, P.A., 245 ROBERTS, M., COLE, P. & AMESS, J. The STAPLETON, J.V. see AUSTIN, K.L., 25 haemoglobin-oxygen dissociation curve: in vivo and in STEELE, W.H. see BAIRD, G.M., 1 12P vitro effects of five P-adrenoceptor antagonists and lig- STEFONI, S., COLI, L., MOSCONI, G. & PRANDINI, R. nocaine, 19 Ibopamine (SB 7505) in normal subjects and in chronic TRENK, D. see JAHNCHEN, E., 361 renal failure: a preliminary report, 69 TSE, T.F. see LEE, P.K., 339 STEINER, J.A. see CLANCY, A., 428P TSUJIMOTO, G., HORAI, Y., ISHIZAKI, T. & ITOH, K. STEPANSKI, E. see ROTH, T., 31S Hydralazine-induced peripheral neuropathy seen in a STEVENSON, I.H. see MORELAND, T.A., 1 11P Japanese slow acetylator patient, 622 STEVENSON, I.H. see SWIFT, C.G., 413P TURNER, P. see BARBAT, J., 117P STONE, BARBARA M. see CANNINGS, R., 410P TURNER, P. see GHOSE, KARABI, 122P STONE, BARBARA M. see JONES, MIRANDA M.C., TURNER, P. see HAMER, J., 426P 123P TURNER, P. see HENRY, J.A., 119P STONE, BARBARA M. see NICHOLSON, A.N., 123P TURNER, P. see HONG, C.Y., 385 INDEX 644

TURNER, P. see LIMA, D.R.A., 120P WALTER, E. see STAIGER, CH., 214 TURNER, P. see LIMA, D.R.A., 521 WARRINGTON, S.J. see BARBAT, J., 117P TURNER, P. see LIMA, D.R.A., 215 WATT, M.H. see SIMPSON, R.J., 96 TURNER, P. see LIMA, D.R.A., 555 WEBSTER, J., BARBER, H.E., HAWKSWORTH, G.M., TURNER, P. see SHARMA, J.N., 433P JEFFERS, T.A., PETERSEN, J., PETRIE, J.C., TURNER, P. see TREMBATH, P.W., 19 BRUNT, P.W., MOWAT, N.A.G. & GRIFFITHS, R. Cimetidine - a clinical and pharmacokinetic study, 333 WEERASURIYA, K. see BARBAT, J., 117P U WEERASURIYA, K. & HAMER, J. A preliminary car- diovascular assessment of alinidine, 398 UEDA, C.T. & DZINDZIO, B.S. Bioavailability of WELLING, P.G. see ROBERTS, D.H., 561 quinidine in congestive heart failure, 571 WENK, M. see HA, H.R., 312 UPPAL, R., GARG, S.K., SHARMA, P.R., VARMA, WHITE, L.O. see REEVES, D.S., 353 V.K. & CHAUDHURY, R.R. Antipyrine kinetics in WHITING, B. see BARCLAY, JOYCE, 203 cannabis smokers, 522 WHITING, B., WILLIAMS, R.L., LORENZI, MARA, VARADY, J.C. & ROBINS, D.S. Effect of naproxen on glucose metabolism and tolbutamide kinetics and V dynamics in maturity onset diabetes, 295 WHITING, P.H. see BARBER, H.E., 1 13P VALAME, S.P. see SHETH, U.K., 251 WIDDOP, B. see CROME, P., 430P VANDENBURG, M.J., CONLON, C. & LEDINGHAM, WILLIAMS, N.E. see CALVEY, T.N., 124P J.M. A comparison of the effects of propranolol and WILLIAMS, N.E. see CALVEY, T.N., 406 oxprenolol on forearm blood flow and skin temperature, WILLLAMS, R.L. see WHITING, B., 295 485 WILLOUGHBY, M.L.N. see BAIRD, G.M., 112P VANDENBURG, M., PARFREY, P., WRIGHT, PAT- WILSON, K.C.M. see GEORGE, A.J., 415P RICIA & LAZDA, E. Hepatitis associated with capto- WILSON, R. see BALANVE, K., 171 pril treatment, 105 WISJMAN, R. see van der KLEUN, E., 85S VAN DER VELDE, E.A. & DRIESSEN, 0. Prediction of WRIGHT, PATRICIA see VANDENBURG, M., 105 phenytoin dosage in relation to the variability of pheny- WONG, K. see DALAL, J.J., 265 toin plasma concentration, 41 VARADY, J.C. see WHITING, B., 295 VARMA, V.K. see UPPAL, R., 522 VERE, D.W. see LrTLEJOHNS, D.W., 319 y VIGANDER, T. see ASLASKEN, A., 269 116P YATES, R.A. see PEET, M., 212 VOLANS, G.N. see CHADWICK, D., YEUNG, P.F.K. see MIDHA, K.K., 85 VREE, T.B. see van der KLEIJN, E., 85S VRHOVAC, B. see PLAVSIC, F., 533

z w ZAREIAN, K. see CUMBERBATCH, M., 565 WADE, P. see BlTTENCOURT, P., 437P ZISOOK, S. see JALL, R.C.W., 99S WAINSCOTT, G. see CROME, P., 430P ZORICK, F. see ROTH, T., 31S SUBJECT INDEX

A ABA-571 Cl, new mucolytic agent to protect against Alcohol, effects of, on benzodiazepine metabolism and aspirin-induced blood loss in man, 626 efficacy, 85S Acebutolol, acute effects of, on cardiovascular function in Aldosterone, bioassay and therapeutic potency of antagon- man, 265 ists of, 426P , effects of, on lymphocyte isoprenaline-stimulated cyc- plasma levels of, following MK 421 in healthy subjects, lic AMP production, 555 461 Acetaminophen, lack of effect of valproate on disposition , plasma levels of, following spironolactone in thiazide- of, in epileptic patients, 391 induced hypokalaemia, 153 Acetanilide, pharmacokinetics of paracetamol and, before Alinidine, cardiovascular effects of, in healthy volunteers, and during phenytoin administration, 591 116P Acetylator phenotype, further evidence for differences in, , preliminary cardiovascular assessment of, 398 in metabolism of hydralazine in man, 345 Alprenolol, binding of, to human serum albumin, a1-acid Acetylphenylbydrazine, in vitro study of tolerability of, in glycoprotein and human serum, 125P G-6-PD-deficient subjects, 251 Aminophyl}ine, comparative pharmacokinetics of al-Acid glycoprotein, binding of f-adrenoceptor antagon- theophylline and, in man, 269 ists to, 125P , metabolic actions of intravenous, alone or combined Adrenaline, changes in plasma levels of, during and after with salbutamol, 197 treatment with tiamenidine and clonidine, 73 , oral sustained-release, in medical inpatients - a com- , dose-response effects of, on human hand veins follow- ment, 387 ing local infusion, 237 , oral sustained-release, in medical inpatients - a reply, , HPLC and electrochemical detection for simultaneous 387 determination of a-methyldopa, and a- Amitriptyline, biological half-life of, 122P methylnoradrenaline in plasma, 435P Ampicillin, effect of, on availability of sulphapyridine fol- urinary excretion of, in psychiatric patients treated with lowing oral sulphasalazine in man, 423P mianserin, 103 Amylase, effect of ranitidine on clearance ratio of, and a-Adrenoceptor blockers, investigation of effects of creatinine, 408 neuroleptics as, in human iris in vivo, 416P Analgesics, clinical assessment of, 319 P-Adrenoceptor antagonists, binding of, to human serum , efficacy of paracetamol in post-operative dental pain, albumin, a1-acid glycoprotein and human serum, 125P 123P , cardiovascular effects of SKF 92657, 428P , metabolic and respiratory effects of nefopam in human , effect of pH on plasma protein binding of a series of, volunteers, 209 119P , methods in clinical assessment of, 319 , haemoglobin-oxygen dissociation curve following, 19 Angina, possible mechanisms of action of oxyfedrine as a is there a relationship between the physical properties useful drug in, 307 and cardioselectivity of?, 402 Angiotensin I, effects of captopril on plasma concentrations 3-Adrenoceptor blockers, and the blood-brain barrier, 549 of, in normotensive sodium-replete subjects, 121P -, efficacy and pharmacokinetics of betaxolol, 171 Aagiotensin H, plasma levels of, following MK 421 in l,ymphocyte cyclic AMP in hypertensive patients healthy subjects, 461 treated with, 120P Angiotensin converting enzyme, control of essential hyper- , metoprolol as sustained release formulation is a long- tension with captopril which is an inhibitor of, 469 acting, 518 inhibiting effect of MK 421 and its lysine analogue on, Adverse drug reaction, difficulties in assessing, in relation to in healthy subjects, 461 the benzodiazepines, lOSS Antidepressants, effect of caroxazone a new, on Age, comparison of atenolol and propranolol in young and monoamine oxidases in healthy volunteers, 511 elderly subjects, 1 18P , new assay procedure for trazodone a new, 505 , effect of cimetidine on cerebral blood flow in elderly Antiepileptic drugs, methods in assessment of, 443 patients and young healthy volunteers, 93 Anti-psychotic drugs, methods of assessment of, 225 effect of, on digitoxin pharmacokinetics, 401 Antipynne, comparative effects of ICI 125,211 and , effect of, on measured responses to single doses of oral cimetidine on kinetics of, 214 temazepam, 413P comparison of in vivo and in vitro rates of oxidation of, , effect of, on pharmacokinetics of metoprolol and its in man, 419P metabolites, 287 , kinetics of, in cannabis smokers,522 , effect of, on prazosin disposition, 427P , pharmacokinetics of, in children, 420P , effect of, on total and free serum haloperidol in Anxiety, differential effect of diazepam on short term mem- schizophrenic patients, 377 ory in subjects with high or low level, 41 1P , influence of, on plasma protein binding of haloperidol, Appetite, effect of zimelidine on body weight and, 96 430P Arachidonic acid, time course changes in levels of, and 646 INDEX

several prostaglandins in human skin following ul- some considerations on the role of, in treatment of traviolet B irradiation, 109P depression, 23S Aspirin, assessment of a new mucolytic agent to protect -, studies of contingent negative variation with, 410P against blood loss induced by, in man, 626 , studies with triazolam in approaches in evaluation of in vitro study of tolerability of, in G-6-PD-deficient hypnotics, 37S subjects, 251 , use of, in clinical practice, 5S local buccal mucosal effects of, and relationship to , use of short- and long-acting hypnotics in clinical gastrointestinal damage, 528 medicine, 61S Asthma, comparison of spincaps and metered dose aerosols Betabhstine, effect of methanesulphonate of, on cerebral for administration of sodium cromoglycate in children blood flow, 308 suffering from, 383 Betaxolol, effect of pH on plasma protein binding of, 119P prednisolone pharmacokinetics compared between , efficacy and pharmacokinetics of, a cardioselective - night and day in subjects suffering from, 303 adrenoceptor blocker, 171 salivary and urine theophylline levels in management Bilirubin, effect of PCN on clearance of, in man, 99 of, in children 434P Bioavailability, comparative, of some sustained release should the maximum or mean FEV1 be used for bron- theophylline preparations in normal volunteers, 433P chodilator aerosol evaluation in patients with acute, , effect of metoclopramide on, of long-acting prop- 631 ranolol, 517 Atenolol, ability of, to cross the blood-brain barrier and , of conventional and sustained-release mexiletine cap- enter the CSF, 549 sules in volunteers and patients, 11 6P binding of, to HSA, AGP and human serum, 125P , of oral verapamil, 426P effect of, on exercise tachycardia in healthy volunteers of quinidine in congestive heart failure, 571 compared with that of bexatolol, 171 , of rectally-administered diazepam in adult epileptic effect of, on haemoglobin-oxygen dissociation curve, patients, 437P 19 Blood-brain bamrier, P-adrenoceptors and the, 549 effects of, on lymphocyte isoprenaline-stimulated cyc- Blood flow, comparison of effects of propranolol and ox- lic AMP production, 555 prenolol on forearm, 485 effect of pH on human plasma protein binding of, 1 19P physiological and pharmacological variability in esti- lymphocyte cyclic AMP in hypertensive patients mated hepatic, in man, 491 treated with, 120P Blood pressure, acute effects of acebutolol on, in suspected pharmacokinetics of propranolol and, in young and coronary artery disease, 265 elderly subjects, 1 18P , changes in, during and after treatment with Azapropazone, plasma protein binding of, in patients with tiamenidine and clonidine, 73 kidney and liver disease, 361 , effect of alinidine on, in healthy volunteers, 398 , effects of captopril on, in normotensive, sodium- replete subjects, 121P , effects of caroxazone on, response to intravenous B tyramine, 605 , effects of caroxazone on, response to oral tyramine, Benzodiazepines, A clinical review: proceedings of a con- 611 ference on,1 S- 120S effect of cimetidine on, in chronic airway obstruction a neuroendocrine approach to tolerance to, and depen- and in normal lung function, 339 dence on, 526 , effect of coffee and cigarette smoking on, in untreated a summary of pharmacokinetic properties, 11S and diuretic-treated hypertensive patients, 428P are they overused and abused?, 71S , effect of SKF 92657 on, in healthy volunteers, 428P bias in elucidation of subjective side-effects to, 11lS effect of varying doses of alinidine on resting and clinical review of, an overview, 117S exercise, in healthy volunteers, 1 16P difficulties in assessing the adverse effects of drugs, , following captopril in essential hypertension, 469 105S nefopam shown not to have any effect on, 209 discussion on review of evaluation of side-effects and Blood vessels, comparison of effects of hydrallazine, handling of data, 115S diazoxide, sodium nitrite and sodium nitroprusside on discussion of review of use of, in clinical medicine, 55S human isolated arteries and veins, 57 double-blind, crossover studies of efficacy of triazolam Body surface, should clearance be normalized to, or to lean compared with nitrazepam and with oxazepam in in- body mass?, 523 somnia, 43S Body weight, effect of zimelidine on appetite and, 96 effects of, on sleep and wakefulness, 31S Brain, ability of P-adrenoceptor blockers to cross the blood- efficacy of some, for day-time sleep, 123P brain barrier and enter the CSF, 549 factors influencing activity and fate of, in the body, 85S Bronchitis, effect of inhaled salbutamol after maximally in the treatment of depressive, borderline personality effective intravenous dose of theophylline in chronic, and schizophrenic disorders, 17S 203 monitored release of triazolam in the United Kingdom, Bronchodilatation, effect of inhaled salbutamol following 51S intravenous theophylline in chronic bronchitis, 203 paradoxical reactions to, 99S Bronchodilators, should the maximum or mean FEV1 be relationship between serum concentrations of, and used for evaluation of aerosol, in acute asthmatics?, peak velocity of saccadic eye movements, 437P 631 INDEX 647

C Circadian variations, in signs and symptoms of rheumatoid arthritis and in therapeutic effectiveness of flurbipro- fen at different times of day, 477 Caffeine, used to evaluate simple method to measure drug Clearance, should, be normalized to body surface or to lean effects on human sperm motility, 385 body mass?, 523 Calcium, clearance of, following piretanide in advanced Clinical pharmacologists, need for, in developing countries, renal insufficiency, 63 457 Cannabis, antipyrine kinetics in smokers of, 522 Clinical pharmacology, in developing countries - a personal Captopril, control of essential hypertension with, 469 view, 457 , effects of, in normotensive, sodium-replete subjects, methods in: assessment of analgesics, 319 121P , methods in: assessment of antiepileptic drugs, 443 , hepatitis associated with treatment with, 105 , methods in: assessment of anti-psychotic drugs, 225 Carbamazepine, effect of, on antipyrine kinetics in children, , methods in: assessment of neuromuscular transmis- 420P sion, 537 , rapid and sensitive high-pressure liquid chromato- , methods in: clinical assessment of depression, 5 graphic method for monitoring levels of, in serum, 393 , methods in: assessment of extrapyramidal disorders, Carbon dioxide, ventilatory response to, following oral 129 nefopam in human volunteers, 209 -, of prazosin: further discussion, 314 Cardiovascular system, acute effects of acebutolol on func- Clinical practice, use of benzodiazepines in, 5S tioning of, in man, 265 Clinical trial, basic program for constructing dispensing list , effects of chronic oral cimetidine on, in man, 497 for randomized, 617 Caroxazone, effect of, a new antidepressant on monoamine reviews and the journal of negative results - a personal oxidases in healthy volunteers, 511 view, 15 effects of, on pressor response to intravenous tyramine Clobazam, diurnal variation of kinetics of, in man, 436P in man, 605 , plasma concentrations of, in healthy volunteers and in effects of, on pressor response to oral tyramine in man, epileptic patients, 618 611 Clonidine, changes in blood pressure, plasma Cefoperazone, decreased extrarenal clearance of, in catecholamines and plasma renin activity during and hepatocellular diseases, 389 after treatment with, 73 Cefoxitin, effect of probenecid on pharmacokinetics and , comparison of cardiovascular effects of, with those of distribution of, in healthy volunteers, 353 alinidine in healthy volunteers, 1 16P Cephradine, pharmacokinetics of intravenous, with or with- , pharmacodynamic study of mianserin and its interac- out probenecid, 561 tion with, 122P Cerebral blood flow, and cimetidine in elderly patients, 93 Coffee, effect of cigarette smoking and, in untreated and , effect of betahistine methanesulphonate on, 308 diuretic-treated hypertensive patients, 428P effect of intravenous disopyramide on, in volunteers, CompLiance, does the frequency of daily dosage influence, 310 with digoxin therapy?, 31 Cerebrospinal fluid, comparison of several P-adrenoceptor , new technique for recording, of human hand veins, 237 blockers in their ability to cross the blood-brain barrier Computer program, for constructing dispensing list for ran- and enter, 549 domized clinical trial, 617 , pilot study of methotrexate salivary levels as an index Congestive heart failure, bioavailability of quinidine in, 571 of levels of, in children, 1 12P Contingent negative variation, studies of, with temazepam, Clorazepate, use of, in clinical practice in the United States, 410P 5S Corticotrophin releasing factor, neural mechanisms con- Chlordiazepoxide, use of, in clinical practice in the United trolling secretion of, - a comment, 216 States, 5S , neural mechanisms controlling secretion of, - a reply, Chlorpromazine, effect of, on 5-HT-induced platelet ag- 219 gregation in schizophrenic patients, 255 Creatinine, clearance of, following ibopamine in chronic , serum levels of, during probucol treatment in hyper- renal failure, 69 cholesterolaemia, 531 , clearance of, following piretanide in renal insufficien- Cinetidine, a clinical and pharmacokinetic study, 333 cy,63 , cerebral blood flow and, in elderly patients, 93 , effect of ranitidine on clearance ratio of amylase and, comparative effects of ICI 125,211 and, on antipyrine 408 kinetics, 214 Cyclic AMP, comparison of four 3-adrenoceptor blockers , effects of chronic oral therapy with, on cardiovascular on isoprenaline-stimulated production of, by lympho- system in man, 497 cytes, 555 , effect of simultaneous dose of metoclopramide and , influence of pH on in vitro activity of prostacyclin on propantheline on gastrointestinal absorption of, 629 production of human lymphocyte, 125 , haemodynamic responses to intravenous, in normal l,ymphocyte, in hypertensive patients treated with P- lung function and in chronic airway obstruction, 339 adrenoceptor blockers, 120P , variability in the enzyme inhibiting effect of, in man, , partial agonist activity of practolol on human lympho- 421P cyte production of, 521 Circadian rhythm, in disposition of prednisolone and its Cyproheptadine, effect of, in suppressing adverse reactions effect on efficacy of dosage in asthma, 303 following use of diethylcarbamazine in patients with , in kinetics of clobazam in man, 436P onchocerciasis, 418P 648 INDEX

D Dopanine, plasma DOPA may be precursor of urine free, 79 Debrisoquine, evidence for enzymatic defect in 4- Doxapram, normal pharmacokinetics of, in a patient with hydroxylation of, by human liver, 89 renal failure and hypothyroidism, 305 Dependence, a neuroendocrine approach to ben- Duodenl nicer, effect of cimetidine on, over six months and zodiazepine, 526 effect of sudden withdrawal, 333 Depression, availability of tryptophan after loading in pa- Dyskiesias, methods in assessment of, 129 tients with, 414P -, clinical review of benzodiazepines in treatment of, 17S , platelet monoamine oxidase activity and post-natal, 415P E , methods in clinical assessment of, 5 , some considerations on the role of benzodiazepines in Elctocardiogamm, effect of quinidine and its metabolites treatment of, 23S on the, in normal subjects, 187 Dermatology, kinetics of 8-methoxypsoralen and response Electrochemical detection, with high-pressure liquid to long wave ultraviolet light in patients with der- chromatography for simultaneous determination of en- matological diseases, 424P dogenous catecholamines, a-methyldopa and a- Desmethyldazepam, plasma concentrations of diazepam methylnoradrenaline in plasma, 435P and, during long-term diazepam therapy, 35 Enzyme immunoassay, compared with high-pressure liquid Diabetes, effect of naproxen on glucose metabolism and on chromatography for quinidine determination in serum, kinetics and dynamics of tolbutamide in maturity onset, 312 295 Enzyme induction, do acetanilide and paracetamol kinetics , sulphinpyrazone metabolism in insulin-requiring, over before and during phenytoin administration indicate a a long period, 597 genetic control of?, 591 Diazepam, bioavailability of rectally-administered, in adult , drug metabolizing, in children, 420P epileptic patients, 437P , effect of, on disopyramide metabolism in man, 279 , differential effects of, on short term memory in subjects Enzyme inhibition, variability in, caused by cimetidine in with high or low level anxiety, 41 1P man, 421P , effect of single dose of, following withdrawal on growth Epilepsy, bioavailability of rectally-administered diazepam hormone secretion, 526 in adult patients suffering from, 437P -, plasma concentrations of desmethyldiazepam and, -, comparison of clobazam plasma levels in normal sub- during long-term therapy with, 35 jects and in patients with, 618 , sex-related differences in plasma protein binding of lack of effect of valproate on paracetamol disposition in lignocaine and, 245 patients with, 391 , use of, in clinical medicine in the United Kingdom, 61S Ethinyloestradiol, in vitro metabolism of, by human jejunal -, use of, in clinical practice in the United States, 5S mucosa, 275 Diazoxide, comparison of effects of, with those of hydral- , plasma concentrations of, in smokers and non- lazine, sodium nitrite and sodium nitroprusside on smokers, 438P human isolated arteries and veins, 57 Extrapyramidal disorders, methods in assessment of, 129 Dichioralphenzone, elimination of, as an index of drug metabolizing ability in children, 1 11P Diethykarbanazine, efficacy of indomethacin, prednisone or cyproheptadine in suppressing adverse reactions F following, in patients with onchocerciasis, 418P Digitoxin, effect of age on pharmacokinetics of, 401 Fatty acid, effect of, on total and free serum haloperidol in Digoxin, early and late effects of, on sodium transport and schizophrenic patients, 377 content with Na+K+-ATPase of erythrocytes, 565 Flunitrazepam, use of, in clinical medicine in the United , influence of frequency of daily dosage on compliance Kingdom, 61S with, therapy, 31 Flpenthixol, effect of, on 5-HT-induced platelet aggrega- -, pharmacokinetics of, in patients subjected to its in- tion in schizophrenic patients, 255 teraction with quinidine, 181 Fluphenazine, effect of, on 5-HT-induced platelet aggrega- , serum protein binding unlikely to be involved in the tion in schizophrenic patients, 255 interaction between, and quinidine, 94 Flurazepam, use of, in clinical medicine in the United Dihydroergotamhe, dose-response effects of, on human Kingdom, 61S hand veins following local infusion, 237 Flurbiproten, circadian variations in therapeutic effective- DIhydroxyphenylaanine, specific radioenzymatic assay for, ness of, in rheumatoid arthritis, 477 (DOPA), 79 -, in vitro study of tolerability of ibuprofen and, in G-6- Disopyrnmide, effect of enzyme induction on metabolism PD-deficient subjects, 251 of, in man, 279 Food, effect of, on pharmacokinetics of tolmesoxide in , effect of intravenous, on cerebral blood flow in volun- hypertensive patients, 431P teers, 310 Forced expiratory volume, should the maximum or mean , plasma concentrations and protein binding of, during reading of, be used for bronchodilator aerosol evalua- chronic oral therapy with, 369 tion in acute asthmatics?, 631 DL-308, effect of, on mydriatic response of pupil to Frusemide, effects of either, or piretanide on phar- methoxamine, 416P macokinetics of gentamicin, 1 13P INDEX 649

G Human serum albumin, binding of 0-adrenoceptor an- tagonists to, 125P Gail bladder, probucol and effects on, in hypercholes- Huntington's disease, methods in assessment of, 129 terolaemia, 53 1 Hydrne, development of peripheral neuropathy in a Gastric acid, inhibition of secretion of, with FPL-52694, a Japanese slow acetylator patient following, 622 mast cell stabilizer, 53 , effect of, on systolic time intervals, 11 7P Gentamicin, effects of either frusemide or piretanide on , further evidence for an acetylator phenotype differ- pharmacokinetics of, 1 13P ence in metabolism of, in man, 345 D-Glucaric acid, excretion of, in normal subjects and in , with propranolol compared with SKF 92657 in healthy renal dysfunction, 92 volunteers, 428P Glucose, blood levels of, during intravenous salbutamol and , comparison of effects of, with those of diazoxide, aminophyiline alone or in combination, 197 sodium nitrite and sodium nitroprusside on human , effect of naproxen on metabolism of, in maturity onset isolated arteries and veins, 57 diabetes, 295 5-Hydro ptamine, dose-response effects of, on human , effects of oral, in lime juice on isoniazid kinetics, 423P hand veins following local infusion, 237 Glycopyrrolate, comparison of, given before or with neo- , effects of neuroleptic drugs on platelet aggregation stigmine for reversal of residual neuromuscular block, induced by, in schizophrenic patients, 255 417P , reliability of platelet aggregation induced by, in Growth hormone, secretion of, in response to diazepam schizophrenic patients treated with neuroleptic drugs, following diazepam withdrawal, 526 261 Hypercholesterolnemia, probucol and, 531 Hypertension, control of essential, with captopril, 469 H , effect of coffee and cigarette smoking in untreated and diuretic-treated patients with, 428P H2-Receptor antagonist, effect of ranitidine a new, on , effect of food on pharmacokinetics of tolmesoxide in, amylase/creatinine clearance ratio, 408 431P Haemoglobin, dissociation curve of, with oxygen in exami- , effects of tiamenidine and clonidine during and after nation of effects of P-adrenoceptor antagonists and treatment in, 73 lignocaine, 19 -, variation in response to spironolactone in patients with Haloperidol, effect of, on 5-HT-induced platelet aggrega- thiazide-induced, 153 tion in schizophrenic patients, 255 Hypothyroidism, normal pharmacokinetics of doxapram in , effect of, on mydriatic response of pupil to methox- a patient with renal failure and, 305 amine, 416P -, influence of age and disease states on plasma protein binding of, 430P total and free serum levels of, in schizophrenic patients, I 377 Heart rate, effect of alinidine on, in healthy volunteers, 398 Ibopamine, preliminary report on effects of, in normal , effect of betaxolol on exercise, in healthy volunteers, subjects and in chronic renal failure, 69 171 Ibuprofen, in vitro study of tolerability of, and flurbiprofen -, effects of intravenous salbutamol and aminophylline in G-6-PD-deficient subjects, 251 singly and in combination on, in healthy volunteers, ICI 125,211, comparative effects of, and cimetidine on 197 antipyrine kinetics, 214 , effect of SKF 92657 on, in healthy volunteers, 428P Imipramine, effect of, on monoamine oxidases compared , effect of varying doses of alinidine on resting and with that of caroxazone, 511 exercise, in healthy volunteers, 1 16P Indocyamne green, clearance of, as a measure of physiologi- Hepatic blood flow, physiological and pharmacological var- cal effects on hepatic blood flow in normotensive man, iability in estimated, in man, 491 491 Hepatits, associated with captopril treatment, 105 Indomethacin, effect of, in suppressing adverse reactions Heroin, induces morphine-like insomnia in non-dependent following diethylcarbamazine in patients with on- human addicts, 159 chocerciasis, 418P High-pressure liquid chronatography, for assay of ketopro- , local buccal mucosal effects of, and relationship to fen in plasma and urine and application to determining gastrointestinal damage, 528 urinary excretion of free and conjugated ketoprofen Insomnia, double-blind crossover studies of efficacy of following oral administration of Orudis®9 in man, 395 triazolam compared with nitrazepam and with ox- -, rapid and sensitive method for monitoring car- azepam in, 43S bamazepine levels in serum, 393 , morphine-like, from heroin in non-dependent human reverse-phase, for assay of trazodone in human plasma, addicts, 159 505 , studies with triazolam in approaches in evaluation of with electrochemical detection for simultaneous deter- hypnotics, 37S mination of endogenous catecholamines, a- Inslin, blood levels of, during intravenous salbutamol and methyldopa and a-methylnoradrenaline in plasma, aminophylline alone or in combination, 197 435P Isoniazid, effects of oral glucose in lime juice on kinetics of, , compared with enzyme immunoassay for determina- 423P tion of serum quinidine, 312 , inhibition of vitamin D metabolism by, in man, 422P 650 INDEX

Isoprenaline, compared with practolol for effect on human Lymphocytes, comparison of effects of different fi- lymphocyte cyclic AMP production, 521 adrenoceptor blockers on isoprenaline-stimulated cyc- , comparison of four 0-adrenoceptor blockers on lym- lic AMP production by, 555 phocyte cyclic AMP production stimulated by, 555 effect of, on human lymphocyte cyclic AMP production in vitro compared with that of prostacyclin, 125 M Isosorbide dinitrate, kinetics of, and relationship to phar- macological effects, 579 Mast cells, inhibition of gastric acid secretion with FPL- Isoxepac, local buccal mucosal effects of, and relationship to 52694, a stabilizer of, 53 gastrointestinal damage, 527 Memory, differential effect of diazepam on short term, in subjects with high or low anxiety, 41 1P Mestrnol, in vitro metabolism of, by human jejunal mu- cosa, 275 J Methotrexate, pilot study of salivary levels of, as an index of CSF levels in children, 1 12P Jejunum, in vitro metabolism of synthetic steroids by Metboxamine, effects of several neuroleptics on mydriatic human, 275 response of pupil to, 416P 8-Methoxypsoralen, kinetics of, and response to long wave ultraviolet light in patients with dermatological dis- K eases, 424P oa-Methyldopa, HPLC and electrochemical detection for Ketoprofen, high-pressure liquid chromatographic assay simultaneous determination of endogenous for levels of, in plasma and urine and application to catecholamines, and a-methylnoradrenaline in plasma, determining urinary excretion of free and conjugated, 435P following oral Orudis® in man, 395 N-Methyldopamine, effects of di-isobutyric ester of, in Kidney, acute effect of high dose of piretanide in advanced chronic renal failure, 69 insufficiency of, 63 cx-Methylnoradrenaile, HPLC and electrochemical detec- , enhanced drug metabolism and dysfunction of, 92 tion for simultaneous determination of endogenous normal pharmacokinetics of doxapram in a patient with catecholamines, and ax-methyldopa in plasma, 435P failure of, and hypothyroidism, 305 Metoclopramide, effect of, on bioavailability of long-acting -, plasma protein binding of azapropazone in patients propranolol, 517 with diseased, 361 -, effect of simultaneous administration of oral, on ab- , preliminary report on effects of ibopamine in normal sorption of paracetamol in healthy volunteers, 430P subjects and in chronic renal failure, 69 , effect of simultaneous dose of, and propantheline on gastrointestinal absorption of cimetidine, 629 Metoprolol, ability of, to cross the blood-brain barrier and enter the CSF, 549 L , binding of, to HSA, AGP and human serum, 125P comparison of duration of effect of, and a sustained- Labetalol, effect of, on hepatic blood flow in normotensive release formulation of, 518 man, 491 , effect of age on pharmacokinetics of, and its metabo- Lactic acidosis, is there a genetic predisposition to lites, 287 phenformin-induced?, 418P Mexiletine, absorption of conventional and sustained- Lean body mass, should clearance be normalized to body release, capsules in volunteers and patients, 1 16P surface or to?, 523 Mianserin, effect of, on urinary catecholamine excretion in Levonorgestrel, in vitro metabolism of, by human jejunal psychiatric patients, 103 mucosa, 275 , pharmacodynamic studies on, and its interaction with Lignocalne, effect of, on haemoglobin-oxygen dissociation clonidine, 122P curve, 19 MK 421, effect of, and its lysine analogue on components of , sex related differences in plasma protein binding of the renin system in healthy subjects, 461 diazepam and, 245 Monoamine oxidase, effects of caroxazone a reversible Liver, decreased extrarenal clearance of cefoperazone in inhibitor of, on pressor response to intravenous cellular diseases of, 389 tyramine, 605 , evidence for enzymatic defect in 4-hydroxylation of , effects of caroxazone a reversible inhibitor of, on pres- debrisoquine by human, 89 sor response to oral tyramine, 611 , physiological and pharmacological variability in esti- Monoamine oxiduse activity, effects of caroxazone on, in mated blood flow through, in man, 491 healthy volunteers, 511 , plasma protein binding of azapropazone in patients , puerperal mood changes and platelet, 415P with diseased, 361 , single dose of tranylcypromine inhibits platelet, 212 Lorazepam, use of, in clinical medicine in the United King- Mono-N-dealkyldlsopyramide, plasma concentrations and dom, 61S protein binding of, during chronic oral disopyramide , use of, in clinical practice in the United States, 5S therapy, 369 Lungs, haemodynamic responses to intravenous cimetidine Myastbenia gravis, clinical response and plasma levels of in patients with normal functioning, and in patients pyridostigmine in, 435P with chronic airway obstruction, 339 Myoclonus, methods in assessment of, 129 INDEX 651

N p

Naproxen, effect of, on glucose metabolism and tol- Psediatrics, dichloralphenazone elimination as an index of butamide kinetics and dynamics in maturity onset diab- drug metabolizing ability in children, 11 1P etes, 295 , drug metabolizing enzyme induction in children, 420P Nefopam, respiratory and metabolic effects of, in human , pilot study of salivary methotrexate as an index of CSF volunteers, 209 levels in children, 1 12P Neostigmine, comparison of glycopyrrolate given before or , salivary and urine theophylline levels in management with, for reversal of residual neuromuscular block, of childhood asthma, 434P 417P Pain, analgesic effect of paracetamol in post-operative den- Neuromuscular block, comparison of glycopyrrolate given tal, 123P before or with neostigmine for reversal of residual, Paracetamol, analgesic effect of, in post-operative dental 417P pain, 123P Neuromuscular blockers, effects of, on metabolism and effect of simultaneous administration of oral metoclop- efficacy of benzodiazepines, 85S ramide on absorption of, in healthy volunteers, 430P Neuromuscula tranmisson, clinical methods for assess- lack of effect of valproate on disposition of, in epileptic ment of, 537 patients, 391 Nitrazepam, double-blind crossover studies to compare , metabolism of, in overdosed patients, 11OP triazolam and, in insomnia, 43S pharmacokinetics of acetanilide and, before and during pharmacokinetics and psychomotor effects of, in young phenytoin administration, 591 males and females, 412P Pemoline, studies of prolintane and, on sleep in man, 123P Noradrenaline, changes in plasma levels of, during and after Peripheral neuropathy, development of, following hyd- treatment with tiamenidine and clonidine, 73 ralazine in a Japanese slow acetylator patient, 622 , dose-response effects of, on human hand veins follow- Perphene, radioimmunoassay for, in human plasma, 85 ing local infusion, 237 Personal view, clinical pharmacology in developing coun- -, effects of captopril on plasma concentrations of, in tries, 457 normotensive, sodium-replete subjects, 121P Personalty disorders, clinical review of use of ben- , HPLC and electrochemical detection for simultaneous zodiazepines in treatment of borderline cases of, 17S determination of a-methyldopa, and a-methyl- Pethidine, clearance of, during continuous intravenous in- noradrenaline in plasma, 435P fusions postoperatively, 25 urinary excretion of, in psychiatric patients treated with pH, effect of, on human plasma protein binding of series of mianserin, 103 P-adrenoceptor antagonists, 1 19P Nordiazepam, use of, in clinical medicine in the United , influence of, on in vitro activity of prostacyclin on Kingdom, 61S human lymphocyte cyclic AMP production, 215 Norgestrel, plasma concentrations of, in smokers and non- Phenformin, is there a genetic predisposition to lactic smokers, 438P acidosis induced by?, 418P Phenoperidine, plasma levels and urinary excretion of, and its metabolites in volunteers, 124P Phenoxybenzamine, effect of, on hepatic blood flow in normotensive man, 491 0 Phenytoin, effects of, on disopyramide metabolism in man, 279 Onchocerciasis, effect of various drugs in suppressing , pharmacokinetics of acetanilide and paracetamol be- adverse reactions following diethylcarbamazine in fore and during administration of, 591 patients with, 418P , prediction of dosage of, in relation to variability of Oral contraceptives, effect of cigarette smoking on plasma plasma concentration of, 41 concentrations of, 438P , serum protein binding of, in pregnant women, 409P Overdose, high plasma salicylate levels following, 625 Pindolol, binding of, to HSA, AGP and human serum, 125P Oxazepam, double-blind crossover studies to compare , effects of, on lymphocyte isoprenaline-stimulated cyc- triazolam and, in insomnia, 43S lic AMP production, 555 use of, in clinical medicine in the United Kingdom, 61S , effect of pH on plasma protein binding of, 1 19P , use of, in clinical practice in the United States, 5S Piretanide, acute effect of high dose of, in advanced renal Oxprenolol, ability of, to cross the blood-brain barrier and insufficiency, 63 enter the CSF, 549 , effects of combination of triamterene and, in healthy -, binding of, to HSA, AGP and human serum, 125P subjects, 106 , comparison of effects of propranolol and, on forearm , effects of either frusemide or, on pharmacokinetics of blood flow and skin temperature, 485 gentamicin, 113P -, effect of, on exercise tachycardia in healthy volunteers Phlsma, comparison of theophylline and aminophylline compared with that of betaxolol, 171 levels in, following oral administration and intravenous , effect of pH on plasma protein binding of, 1 19P infusion, 269 Oxyfedrine, possible mechanisms of action of, as an anti- , concentrations of metoprolol and its metabolites in, anginal drug, 307 and age-related effects, 287 Oxygen, dissociation curve of haemoglobin and, in exami- , high-pressure liquid chromatographic assay for keto- nation of effects of P-adrenoceptor antagonists and profen levels in, in man, 395 lignocaine, 19 -, phenoperidine levels in, in volunteers, 124P 652 INDEX

, pyrimethamine levels in saliva and, 101 , comparison of cardiovascular effects of, with those of , relationship between DOPA levels in, and urine free alinidine in healthy volunteers, 1 16P dopamine levels, 79 comparison of effects of, and of oxprenolol on forearm -, sex related differences in lignocaine and diazepam blood flow and skin temperature, 485 levels in, 245 , comparison of plasma levels after conventional and Plasma protein, binding of azapropazone in patients with long-acting, using a radio-receptor assay, 432P kidney and liver disease, 361 , effect of metoclopramide on bioavailability of long- , influence of age and disease states on, binding of acting, 517 haloperidol, 430P -, effect of, on exercise tachycardia in healthy volunteers Plasma protein binding, effect of pH on human, of a series compared with that of bexatolol, 171 of P-adrenoceptor antagonists, 119P , effect of, on hepatic blood flow in normotensive man, Plasma renin actvity, effects of tiamenidine and clonidine 491 on, 73 , effect of, on haemoglobin-oxygen dissociation curve, Platelets, effects of neuroleptic drugs on 5-HT-induced 19 aggregation of, in schizophrenic patients, 255 , effect of pH on plasma protein binding of, 1 19P , puerperal mood changes and monoamine oxidase ac- -, lymphocyte cyclic AMP in hypertensive patients tivity of, 415P treated with, 120P , reliability of 5-HT-induced aggregation of, in schizo- pharmacokinetics of atenolol and, in young and elderly phrenic patients treated with neuroleptic drugs, 261 subjects, 1 18P 'Post-natal bhles', see puerperal mood changes, 415P with hydralazine compared with SKF 92657 in healthy Potassium, blood levels of, during intravenous salbutamol volunteers, 428P and aminophylline alone or in combination, 197 Prorenoate potassum, potency of, relative to spironolac- , clearance of, following piretanide in advanced renal tone at steady-state in man, 1 14P insufficiency, 63 Prostacyclin, influence of pH on in vitro activity of, on , excretion of, following piretanide and triamterene human lymphocyte cyclic AMP production, 125 alone or in combination, 106 Prostadins, time course changes in levels of arachidonic , plasma levels of, following spironolactone in thiazide- acid and, D2, E2, F2a5 and 6-oxo-PGF1,5 in human skin induced hypokalaemia, 153 following ultraviolet B irradiation, 109P Prazepam, use of, in clinical practice in the United States, Puerperal mood changes, and platelet monoamine oxidase 5s activity, 415P Prazosin, effect of age on disposition of, 427P Pule, nefopam shown not to have any effect on rate of, 209 Practolol, effect of, on haemoglobin-oxygen dissociation Pulse rate, effect of coffee and cigarette smoking on, in curve, 19 untreated and diuretic-treated hypertensive patients, effect of pH on plasma protein binding of, 1 19P 428P , partial agonist activity of, on human lymphocyte cyclic Pyridostigmine, clinical response and plasma levels of, in AMP production, 521 myasthenic patients, 435P Prazosin, clinical pharmacology of, - a comment, 221 , kinetics of intravenous, in man, 406 , clinical pharmacology of, - a reply, 222 Pyrimethamine, salivary elimination of, 101 concentration-effect, metabolism and biological activi- ty of metabolites of, - a comment, 221 Q Prednisolone, pharmacokinetics of, compared between night and day in asthmatic and normal subjects, 303 Quinidine, bioavailability of, in congestive heart failure, Prednisone, effect of, in suppressing adverse reactions fol- 571 lowing use of diethylcarbamazine in patients with on- , digoxin pharmacokinetics in patients subjected to in- chocerciasis, 418P teraction of, with digoxin, 181 Pregnancy, effect of, on clearance of benzodiazepines, 85S , effect of, on ECG and systolic time intervals, 187 -, effect of, on serum protein binding of phenytoin, 409P EIA v HPLC for determination of, in serum, 312 Pregnenolone-16x-carbonitrile, effect of, on bilirubin , serum protein binding unlikely to be involved in the clearance in man, 19 interaction between digoxin and, 94 Prlmaquine, in vitro study of tolerability of, in G-6-PD- deficient subjects, 251 R Probenecid, pharmacokinetics of cephradine given in- travenously with and without, 561 Radioimmunoassay, for determination of plasma concen- , effect of, on pharmacokinetics and distribution of trations of sodium cromoglycate in volunteers, 425P cefoxitin in healthy volunteers, 353 , for perphenazine in human plasma, 85 Probucol, and hypercholesterolaemia, 531 Radio-receptor assay, for comparison of plasma levels after Prolntane, studies of pemoline and, on sleep in man, 123P conventional and long-acting propranolol, 432P Pronethane, effect of, on 5-HT-induced platelet aggrega- Ranitidine, effect of, a new histamine H2-receptor antagon- tion in schizophrenic patients, 255 ist, on amylase/creatinine clearance ratio, 408 Propantheline, effect of simultaneous dose of metoclop- Renin, effects of captopril on activity of, in normotensive ramide and, on gastrointestinal absorption of sodium-replete subjects, 121P cimetidine, 629 Rheumatoid arthrits, circadian variations in signs and Propranolol, ability of, to cross the blood-brain barrier and symptoms of, and efficacy of flurbiprofen, 477 enter the CSF, 549 Rifampicin, effects of, on disopyramide metabolism in man, , binding of, to HSA, AGP and human serum, 125P 279 INDEX 653

S tent of, and on erythrocyte ATPase, 565 , excretion of, following piretanide and triamterene Saccdc eye movements, relationship between serum ben- alone or in combination, 106 zodiazepine concentration and peak velocity of, 437P , plasma levels of, following spironolactone in thiazide- Salbutanol, interaction between theophylline and, and induced hypokalaemia, 153 bronchodilator response to, at maximally effective Sodium cromoglycate, plasma concentrations of, deter- plasma theophylline concentrations, 203 mined by a new method, 425P , metabolic actions of intravenous, alone or combined , spincaps or metered dose aerosol, 383 with aminophylline, 197 Sodium nitre, comparison of effects of, with those of Sacylate, high unbound fraction of, in plasma during hydrallazine, diazoxide and sodium nitroprusside on intoxication, 625 human isolated arteries and veins, 57 Salva, pilot study of methotrexate levels in, as an index of Sodium nitroprusside, comparison of effects of, with those CSF levels in children, 1 12P of hydrallazine, sodium nitrite and diazoxide on human -, pyrimethamine levels in, 101 isolated arteries and veins, 57 -, theophylline concentrations in, as a guide for indi- Sotalol, effect of, on exercise tachycardia in healthy volun- vidualization of therapeutic use of theophylline, 533 teers compared with that of bexatolol, 171 -, theophylline levels in, in management of childhood Sperm, simple method to measure drug effects on motility asthma, 434P of human, 385 SB 7505, see ibopamine, 69 Spironobctone, assessment of potency of, relative to SC810 SC8109, assessment of potency of, relative to spironolac- (after single doses), 426P tone after single doses, 426P potency of prorenoate potassium relative to, at steady- Schizophrenia, availability of tryptophan after loading in state in man, 1 14P patients with, 414P -, variation in response to, between patients with clinical review of benzodiazepines in treatment of, 17S thiazide-induced hypokalaemia, 153 , effects of neuroleptic drugs on 5-HT-induced platelet ST567, see alinidine, 116P aggregation in, 255 Sulphapyridine, effect of ampicillin on availability of, fol- , reliability of 5-HT-induced platelet aggregation re- lowing oral sulphasalazine in man, 423P sponses in, when treated with neuroleptic drugs, 261 Sulphasalne, effect of ampicillin on availability of sul- , total and free serum haloperidol levels in, 377 phapyridine following oral, in man, 423P Serum, binding of 3-adrenoceptor antagonists to human, Sulphinpyrazone, metabolism of, during long-term therapy, 125P 597 -, comparison of theophylline and aminophylline levels Systolic time interval, effect of hydralazine on, 1 17P in, following oral administration and intravenous infu- , effect of quinidine and its metabolites on, in normal sion, 269 subjects, 187 , EIA v HPLC for determination of quinidine in, 312 Serum protein, binding of phenytoin in pregnant women, 409P T Sex, effect of, on plasma protein binding of lignocaine and diazepam, 245 Tardive dysinesia, methods in assessment of, 129 Side-effects, bias in elucidation of subjective, 11S Temazepam, effect of ageing on measured responses to , discussion on review of evaluation of, and handling of single doses of oral, 413P data, 115S -, pharmacokinetics and psychomotor effects of, in young SKF 92657, cardiovascular effects of, a new antihyper- males and females, 412P tensive agent with P-adrenoceptor antagonist and pharmacokinetics of, in volunteers and elderly hospital vasodilator properties, 428P in-patients, 123P Skin, comparison of effects of propranolol and oxprenolol , studies of contingent negative variation with, 410P on forearm blood flow and temperature of, 485 , use of, in clinical medicine in the United Kingdom, 61S SL 75212, see betaxolol, 171 Temperature, comparison of effects of propranolol and , effect of, at different doses on haemoglobin-oxygen oxprenolol on forearm blood flow and skin, 485 dissociation curve, 19 , nefopam depresses oral, in a dose-dependent mode, Sleep, clinical review of effects of benzodiazepines on, and 209 wakefulness, 31S Theophyfline, blood levels of, during intravenous sal- , dose-related effects of heroin on human, 159 butamol and aminophylline alone or in combination, efficacy of some benzodiazepines for day-time, 123P 197 , studies of prolintane and pemoline on, in man, 123P , comparative bioavailability of some sustained release Smoking, antipyrine kinetics in cannabis, 522 preparations of, in normal volunteers,433P , effect of cigarette, on plasma concentrations of oral , comparative pharmacokinetics of, and aminophylline contraceptive steroids, 438P in man, 269 effect of coffee and cigarette, in untreated and diuretic- , concentration of, in saliva as a guide for individualiza- treated hypertensive patients, 428P tion of its therapeutic use, 533 Sodium, clearance of, following ibopamine in normal sub- , interaction between salbutamol and, and bron- jects and in chronic renal failure, 69 chodilator response to salbutamol at maximally effec- , clearance of, following piretanide in advanced renal tive plasma concentrations of, 203 insufficiency, 63 , salivary and urine levels of, in management of child- -, early and late effects of digoxin on transport and con- hood asthma, 434P 654 INDEX

Thiazide, inter-patient variation in response to spironolac- , interaction of, with single dose of tranylcypromine in tone for hypokalaemia induced by, 153 healthy volunteers, 212 Thioridazine, effect of, on 5-HT-induced platelet aggrega- tion in schizophrenic patients, 255 , effect of, on mydriatic response of pupil to methox- amine, 416P , effect of, on total and free serum haloperidol in U schizophrenic patients, 377 Thynoxamine, effect of, on mydriatic response of pupil to Ultviolet B, time course changes in levels of arachidonic methoxamine, 416P acid and various prostaglandins in human skin follow- Tiamenidine, changes in blood pressure, plasma ing irradiation with, 109P catecholamines and plasma renin activity during and Ultviolet ligbt, kinetics of 8-methoxypsoralen and re- after treatment with, 73 sponse to long wave, in patients with dermatological Tics, methods in assessment of, 129 diseases, 424P Thnolol, binding of, to HSA, AGP and human serum, 125P Uric add, plasma levels of, following piretanide and triam- , effects of, on lymphocyte isoprenaline-stimulated cyc- terene alone or in combination, 106 lic AMP production, 555 Urine, effect of piretanide on flow of, in advanced renal , lymphocyte cyclic AMP in hypertensive patients insufficiency, 63 treated with, 120P , excretion of, following ibopamine in normal subjects Tolbutamide, effect of naproxen on kinetics and dynamics and in chronic renal failure, 69 of, in maturity onset diabetes, 295 , high-pressure liquid chromatographic assay for keto- Tolerance, a neuroendocrine approach to benzodiazepine, profen levels in, in man, 395 526 , phenoperidine levels in, in volunteers, 124P Tohnesoxide, effect of food on pharmacokinetics of, in , theophylline levels in, in management of childhood hypertensive patients, 431P asthma, 434P Torsion dystona methods in assessment of, 129 Tranylcypromine, effect of, on monoamine oxidases com- pared with that of caroxazone, 511 , interaction of tyramine with single dose of, in healthy V volunteers, 212 Trazodone, a new assay procedure for, and some phar- Valproate, lack of effect of, on paracetamol disposition in macokinetic parameters of, 505 epileptic patients, 391 Triamterene, effects of combination of piretanide and, in Vasodiators, comparison of effects of several, on human healthy subjects, 106 isolated arteries and veins, 57 Trazolam, efficacy of, compared with nitrazepam and with Veins, new technique for recording compliance of human oxazepam in insomnia, 43S hand, 237 , monitored release of, in the United Kingdom, 5 IS Verapamil, biological availability of oral, and evidence that , proceedings of a clinical conference on ben- the metabolites are inactive, 426P zodiazepines in general and, in particular, 1S-120S Visual analogue scale, complication of use of, when using , studies with, in approaches in evaluation of hypnotics, photocopied scales, 98 37S Vitamin D, inhibition of metabolism of, by isoniazid in man, , use of, in clinical medicine in the United Kingdom, 61S 422P Trifluoperazine, effect of, on 5-HT-induced platelet aggregation in schizophrenic patients, 255 Tryptophan, availability of, after loading in patients with depression or schizophrenia, 414P Tyranine, effects of caroxazone on pressor response to z intravenous, in man, 605 , effects of caroxazone on pressor response to oral, in Zi elidine, effect of, a new antidepressant on appetite and man, 611 body weight, 96 INSTRUCTIONS TO AUTHORS

Papers will be considered for publication on all aspects of drug action in man, including chemotherapy. A recent issue of the Journal is a good guide to style. Manuscripts (two copies) should be sent to Professor A. Richens, Department of Pharmacology and Materia Medica, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XN. Copies of full instructions to Authors, published in Br. J. Pharmac. 50, 3-23, may be obtained from Scientific & Medical Division, Macmillan Publishers Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS. Specific points to note are: 1. Manuscript should be typed in double spacing on one side of paper not larger than A4 (206 x 294 mm). There should be a separate title page giving the names and addresses of the authors. A short title of not more than 50 letters should also be suggested. 2. Statement Papers are accepted only if accompanied by a statement that they have not been and will not be published in whole or in part in any other Journal. Ethical considerations of studies reported will be particularly noted by the Editorial Board. 3. Summary (2 copies) This should be a short summary of results and conclusions arranged in numbered paragraphs. 4. Figures These should not be larger than A4 (206 x 294 mm) and may be in the form of original drawings, recorded tracings or high quality photographic prints made from them. Negative prints of kymograph tracings (black on white) should be provided, and both ordinates and abscissae should be calibrated. Lettering on figures should be inserted in pencil. Symbols which are to appear in figures or legends should be chosen from the following:

QO*O *A A V v

Photographs and photomicrographs should be printed on glossy paper and should be larger than the size required for reproduction. 5. Tables These should not have more then 80 characters to a line (counting spaces between columns as 4 characters) and certainly not more than 100 characters to a line, unless absolutely unavoidable. Figure legends and tables should be typed on separate sheets of paper. 6. References These should be collected in alphabetical order at the end of the paper. They should include the authors' names, year of publication (in brackets), title of article, title of publication (abbreviated in accordance with the fourth edition of the World List ofScientific Periodicals), volume number and first and last page numbers. References to books should in addition, include the names of editors, the edition number, where appropriate, and the town of origin and name of publisher. Two page proofs will be supplied, one of which may be retained by the authors. The other should be corrected immediately and returned to the Press Editor, Dr Annmarie Hedges, Department of Clinical Pharmacology, St Bartholom,ew's Hospital, London EC14 7BE. Corrections should be kept to a minimum. Twenty-five reprints will be supplied to the authors free of charge. Additional reprints can be purchased. A reprint order form, which should be returned promptly, will be sent out with the proofs. No reprints of abstracts are supplied. Letters to the Editors As for full papers except they should not be divided into sections. Names and addresses of authors should appear at the end of the letter.